<!DOCTYPE html>
<html>
<head>
<title>Remsma, INN-infliximab</title>
<meta http-equiv="X-UA-Compatible" content="IE=edge">
</head>
<body>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:274pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">ANNEX I </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:297pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:175pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">SUMMARY OF PRODUCT CHARACTERISTICS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:12.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:214pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:12.96pt"> </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 100 mg powder for concentrate for solution for infusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">One vial contains 100 mg of infliximab*. After reconstitution each mL contains 10 mg of infliximab.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">* Infliximab is a chimeric human-murine IgG1 monoclonal antibody produced in murine hybridoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cells by recombinant DNA technology. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Powder for concentrate for solution for infusion (powder for concentrate) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The powder is white. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">CLINICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima, in combination with methotrexate, is indicated for the reduction of signs and symptoms as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">well as the improvement in physical function in: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adult patients with active disease when the response to disease-modifying antirheumatic drugs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(DMARDs), including methotrexate, has been inadequate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adult patients with severe, active and progressive disease not previously treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">methotrexate or other DMARDs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In these patient populations, a reduction in the rate of the progression of joint damage, as measured by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">X-ray, has been demonstrated (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Adult Crohn&#x2019;s disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is indicated for: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment of moderately to severely active Crohn&#x2019;s disease, in adult patients who have not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">responded despite a full and adequate course of therapy with a corticosteroid and/or an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunosuppressant; or who are intolerant to or have medical contraindications for such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment of fistulising, active Crohn&#x2019;s disease, in adult patients who have not responded despite </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a full and adequate course of therapy with conventional treatment (including antibiotics, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">drainage and immunosuppressive therapy). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric Crohn&#x2019;s disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is indicated for treatment of severe, active Crohn&#x2019;s disease in children and adolescents aged </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:732pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">such therapies. Infliximab has been studied only in combination with conventional </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunosuppressive therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:757pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ulcerative colitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is indicated for treatment of moderately to severely active ulcerative colitis in adult patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">who have had an inadequate response to conventional therapy including corticosteroids and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraindications for such therapies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric ulcerative colitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is indicated for treatment of severely active ulcerative colitis in children and adolescents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aged 6 to 17 years, who have had an inadequate response to conventional therapy including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ankylosing spondylitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">responded inadequately to conventional therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Psoriatic arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is indicated for treatment of active and progressive psoriatic arthritis in adult patients when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the response to previous DMARD therapy has been inadequate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima should be administered: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in combination with methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or alone in patients who show intolerance to methotrexate or for whom methotrexate is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraindicated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab has been shown to improve physical function in patients with psoriatic arthritis, and to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">polyarticular symmetrical subtypes of the disease (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ciclosporin, methotrexate or psoralen ultra-violet A (PUVA) (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Posology and method of administration </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima treatment is to be initiated and supervised by qualified physicians experienced in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diagnosis and treatment of rheumatoid arthritis, inflammatory bowel diseases, ankylosing spondylitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">psoriatic arthritis or psoriasis. Remsima should be administered intravenously. Remsima infusions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be administered by qualified healthcare professionals trained to detect any infusion-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">issues. Patients treated with Remsima should be given the package leaflet and the patient reminder </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">card. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">During Remsima treatment, other concomitant therapies, e.g. corticosteroids and immunosuppressants </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be optimised. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is important to check the product labels to ensure that the correct formulation (intravenous or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subcutaneous) is being administered to the patient, as prescribed. Remsima subcutaneous formulation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is not intended for intravenous administration and should be administered via a subcutaneous injection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">only. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Posology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adults (&#x2265;18</span></i><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> years)  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Rheumatoid arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 mg/kg given as an intravenous infusion followed by additional 3 mg/kg infusion doses at 2 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 weeks after the first infusion, then every 8 weeks thereafter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima must be given concomitantly with methotrexate.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Available data suggest that the clinical response is usually achieved within 12 weeks of treatment. If a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patient has an inadequate response or loses response after this period, consideration may be given to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increase the dose step-wise by approximately 1.5 mg/kg, up to a maximum of 7.5 mg/kg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">8 weeks. Alternatively, administration of 3 mg/kg as often as every 4 weeks may be considered. If </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adequate response is achieved, patients should be continued on the selected dose or dose frequency. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">benefit within the first 12 weeks of treatment or after dose adjustment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Moderately to severely active Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg given as an intravenous infusion followed by an additional 5 mg/kg infusion 2 weeks after the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">first infusion. If a patient does not respond after 2 doses, no additional treatment with infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be given. Available data do not support further infliximab treatment, in patients not responding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">within 6 weeks of the initial infusion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In responding patients, the alternative strategies for continued treatment are: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance: Additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusions every 8 weeks or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Re-administration: Infusion of 5 mg/kg if signs and symptoms of the disease recur (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2018;Re-administration&#x2019; below and section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Although comparative data are lacking, limited data in patients who initially responded to 5 mg/kg but </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">who lost response indicate that some patients may regain response with dose escalation (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 5.1). Continued therapy should be carefully reconsidered in patients who show no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapeutic benefit after dose adjustment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fistulising, active Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusions at 2 and 6 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">after the first infusion. If a patient does not respond after 3 doses, no additional treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab should be given. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In responding patients, the alternative strategies for continued treatment are: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance: Additional infusions of 5 mg/kg every 8 weeks or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Re-administration: Infusion of 5 mg/kg if signs and symptoms of the disease recur followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusions of 5 mg/kg every 8 weeks (see &#x2018;Re-administration&#x2019; below and section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Although comparative data are lacking, limited data in patients who initially responded to 5 mg/kg but </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">who lost response indicate that some patients may regain response with dose escalation (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 5.1). Continued therapy should be carefully reconsidered in patients who show no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapeutic benefit after dose adjustment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In Crohn&#x2019;s disease, experience with re-administration if signs and symptoms of disease recur is limited </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and comparative data on the benefit/risk of the alternative strategies for continued treatment are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lacking. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Ulcerative colitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:766pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 weeks after the first infusion, then every 8 weeks thereafter. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Available data suggest that the clinical response is usually achieved within 14 weeks of treatment, i.e. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">three doses. Continued therapy should be carefully reconsidered in patients who show no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapeutic benefit within this time period. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Ankylosing spondylitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 weeks after the first infusion, then every 6 to 8 weeks. If a patient does not respond by 6 weeks (i.e. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">after 2 doses), no additional treatment with infliximab should be given. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Psoriatic arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 weeks after the first infusion, then every 8 weeks thereafter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Psoriasis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 weeks after the first infusion, then every 8 weeks thereafter. If a patient shows no response after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">14 weeks (i.e. after 4 doses), no additional treatment with infliximab should be given. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Re-administration for Crohn&#x2019;s disease and rheumatoid arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If the signs and symptoms of disease recur, infliximab can be re-administered within 16 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">following the last infusion. In clinical studies, delayed hypersensitivity reactions have been uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and have occurred after infliximab-free intervals of less than 1 year (see sections 4.4 and 4.8). The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">safety and efficacy of re-administration after an infliximab-free interval of more than 16 weeks has not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">been established. This applies to both Crohn&#x2019;s disease patients and rheumatoid arthritis patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Re-administration for ulcerative colitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of re-administration, other than every 8 weeks, has not been established (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sections 4.4 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Re-administration for ankylosing spondylitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of re-administration, other than every 6 to 8 weeks, has not been established </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see sections 4.4 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Re-administration for psoriatic arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of re-administration, other than every 8 weeks, has not been established (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sections 4.4 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Re-administration for psoriasis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Limited experience from re-treatment with one single infliximab dose in psoriasis after an interval of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">20 weeks suggests reduced efficacy and a higher incidence of mild to moderate infusion reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">when compared to the initial induction regimen (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Limited experience from re-treatment following disease flare by a re-induction regimen suggests a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">higher incidence of infusion reactions, including serious ones, when compared to 8-weekly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintenance treatment (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Re-administration across indications </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In case maintenance therapy is interrupted, and there is a need to restart treatment, use of a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">re-induction regimen is not recommended (see section 4.8). In this situation, infliximab should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">re-initiated as a single dose followed by the maintenance dose recommendations described above. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Elderly </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Specific studies of infliximab in elderly patients have not been conducted. No major age-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">differences in clearance or volume of distribution were observed in clinical studies. No dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adjustment is required (see section 5.2). For more information about the safety of infliximab in elderly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients (see sections 4.4 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal and/or hepatic impairment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab has not been studied in these patient populations. No dose recommendations can be made </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Crohn&#x2019;s disease (6 to 17 years) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 weeks after the first infusion, then every 8 weeks thereafter. Available data do not support further </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab treatment in children and adolescents not responding within the first 10 weeks of treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Some patients may require a shorter dosing interval to maintain clinical benefit, while for others a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">longer dosing interval may be sufficient. Patients who have had their dose interval shortened to less </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">than 8 weeks may be at greater risk for adverse reactions. Continued therapy with a shortened interval </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be carefully considered in those patients who show no evidence of additional therapeutic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">benefit after a change in dosing interval. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of infliximab have not been studied in children with Crohn&#x2019;s disease below the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">age of 6 years. Currently available pharmacokinetic data are described in section 5.2 but no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommendation on a posology can be made in children younger than 6 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Ulcerative colitis (6 to 17 years) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 weeks after the first infusion, then every 8 weeks thereafter. Available data do not support further </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab treatment in paediatric patients not responding within the first 8 weeks of treatment (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of infliximab have not been studied in children with ulcerative colitis below </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the age of 6 years. Currently available pharmacokinetic data are described in section 5.2 but no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommendation on a posology can be made in children younger than 6 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Psoriasis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of infliximab in children and adolescents younger than 18 years for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">indication of psoriasis have not been established. Currently available data are described in section 5.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">but no recommendation on a posology can be made. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of infliximab in children and adolescents younger than 18 years for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">indications of juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis have not been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">established. Currently available data are described in section 5.2 but no recommendation on a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">posology can be made. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Juvenile rheumatoid arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of infliximab in children and adolescents younger than 18 years for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">indication of juvenile rheumatoid arthritis have not been established. Currently available data are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">described in sections 4.8 and 5.2 but no recommendation on a posology can be made. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Method of administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab should be administered intravenously over a 2 hour period. All patients administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab are to be observed for at least 1-2 hours post-infusion for acute infusion-related reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Emergency equipment, such as adrenaline, antihistamines, corticosteroids and an artificial airway must </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be available. Patients may be pre-treated with e.g., an antihistamine, hydrocortisone and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">paracetamol and infusion rate may be slowed in order to decrease the risk of infusion-related reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">especially if infusion-related reactions have occurred previously (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shortened infusions across adult indications </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In carefully selected adult patients who have tolerated at least 3 initial 2-hour infusions of infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(induction phase) and are receiving maintenance therapy, consideration may be given to administering </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subsequent infusions over a period of not less than 1 hour. If an infusion reaction occurs in association </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with a shortened infusion, a slower infusion rate may be considered for future infusions if treatment is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to be continued. Shortened infusions at doses &gt;6 mg/kg have not been studied (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For preparation and administration instructions, see section 6.6. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity to the active substance, to other murine proteins, or to any of the excipients listed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infections (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with moderate or severe heart failure (NYHA class III/IV) (see sections 4.4 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special warnings and precautions for use </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Traceability </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In order to improve the traceability of biological medicinal products, the tradename and the batch </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">number of the administered product should be clearly recorded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infusion reactions and hypersensitivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab has been associated with acute infusion-related reactions, including anaphylactic shock, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and delayed hypersensitivity reactions (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Acute infusion reactions including anaphylactic reactions may develop during (within seconds) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">within a few hours following infusion. If acute infusion reactions occur, the infusion must be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">interrupted immediately. Emergency equipment, such as adrenaline, antihistamines, corticosteroids </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and an artificial airway must be available. Patients may be pre-treated with e.g., an antihistamine, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hydrocortisone and/or paracetamol to prevent mild and transient effects. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Antibodies to infliximab may develop and have been associated with an increased frequency of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion reactions. A low proportion of the infusion reactions was serious allergic reactions. An </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">association between development of antibodies to infliximab and reduced duration of response has </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">also been observed. Concomitant administration of immunomodulators has been associated with lower </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">incidence of antibodies to infliximab and a reduction in the frequency of infusion reactions. The effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of concomitant immunomodulator therapy was more profound in episodically-treated patients than in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients given maintenance therapy. Patients who discontinue immunosuppressants prior to or during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab treatment are at greater risk of developing these antibodies. Antibodies to infliximab cannot </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">always be detected in serum samples. If serious reactions occur, symptomatic treatment must be given </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and further infliximab infusions must not be administered (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies, delayed hypersensitivity reactions have been reported. Available data suggest an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increased risk for delayed hypersensitivity with increasing infliximab-free interval. Patients should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">advised to seek immediate medical advice if they experience any delayed adverse reaction (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.8). If patients are re-treated after a prolonged period, they must be closely monitored for signs and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">symptoms of delayed hypersensitivity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients must be monitored closely for infections including tuberculosis before, during and after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment with infliximab. Because the elimination of infliximab may take up to six months, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">monitoring should be continued throughout this period. Further treatment with infliximab must not be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">given if a patient develops a serious infection or sepsis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Caution should be exercised when considering the use of infliximab in patients with chronic infection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or a history of recurrent infections, including concomitant immunosuppressive therapy. Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be advised of and avoid exposure to potential risk factors for infection as appropriate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tumour necrosis factor alpha (TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) mediates inflammation and modulates cellular immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">responses. Experimental data show that TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> is essential for the clearing of intracellular infections. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical experience shows that host defence against infection is compromised in some patients treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It should be noted that suppression of TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> may mask symptoms of infection such as fever. Early </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recognition of atypical clinical presentations of serious infections and of typical clinical presentation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of rare and unusual infections is critical in order to minimise delays in diagnosis and treatment.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients taking TNF-blockers are more susceptible to serious infections. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tuberculosis, bacterial infections, including sepsis and pneumonia, invasive fungal, viral, and other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">opportunistic infections have been observed in patients treated with infliximab. Some of these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infections have been fatal; the most frequently reported opportunistic infections with a mortality rate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of &gt;5% include pneumocystosis, candidiasis, listeriosis and aspergillosis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients who develop a new infection while undergoing treatment with infliximab, should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">monitored closely and undergo a complete diagnostic evaluation. Administration of infliximab should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or antifungal therapy should be initiated until the infection is controlled. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Tuberculosis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There have been reports of active tuberculosis in patients receiving infliximab. It should be noted that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the majority of these reports tuberculosis was extrapulmonary, presenting as either local or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disseminated disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Before starting treatment with infliximab, all patients must be evaluated for both active and inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2018;latent&#x2019;) tuberculosis. This evaluation should include a detailed medical history with personal history </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of tuberculosis or possible previous contact with tuberculosis and previous and/or current </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunosuppressive therapy. Appropriate screening tests, (e.g. tuberculin skin test, chest X-ray, and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Interferon Gamma Release Assay), should be performed in all patients (local recommendations may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">apply). It is recommended that the conduct of these tests should be recorded in the patient reminder </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">card. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients who are severely ill or immunocompromised. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If active tuberculosis is diagnosed, infliximab therapy must not be initiated (see section 4.3).  </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">consulted. In all situations described below, the benefit/risk balance of infliximab therapy should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">very carefully considered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If inactive (&#x2018;latent&#x2019;) tuberculosis is diagnosed, treatment for latent tuberculosis must be started with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antituberculosis therapy before the initiation of infliximab, and in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommendations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients who have several or significant risk factors for tuberculosis and have a negative test for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">latent tuberculosis, antituberculosis therapy should be considered before the initiation of infliximab.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Use of antituberculosis therapy should also be considered before the initiation of infliximab in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">confirmed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Some cases of active tuberculosis have been reported in patients treated with infliximab during and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">after treatment for latent tuberculosis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(e.g. persistent cough, wasting/weight loss, low-grade fever) appear during or after infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Invasive fungal infections </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients treated with infliximab, an invasive fungal infection such as aspergillosis, candidiasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pneumocystosis, histoplasmosis, coccidioidomycosis or blastomycosis should be suspected if they </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">develop a serious systemic illness, and a physician with expertise in the diagnosis and treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">invasive fungal infections should be consulted at an early stage when investigating these patients.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Invasive fungal infections may present as disseminated rather than localised disease, and antigen and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antibody testing may be negative in some patients with active infection. Appropriate empiric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antifungal therapy should be considered while a diagnostic workup is being performed taking into </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">account both the risk for severe fungal infection and the risks of antifungal therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For patients who have resided in or travelled to regions where invasive fungal infections such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">histoplasmosis, coccidioidomycosis, or blastomycosis are endemic, the benefits and risks of infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment should be carefully considered before initiation of infliximab therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fistulising Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with fistulising Crohn&#x2019;s disease with acute suppurative fistulas must not initiate infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapy until a source for possible infection, specifically abscess, has been excluded (see section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatitis B (HBV) reactivation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including infliximab, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">who are chronic carriers of this virus. Some cases have had fatal outcome. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:10.56pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients should be tested for HBV infection before initiating treatment with infliximab. For patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">who test positive for HBV infection, consultation with a physician with expertise in the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatitis B is recommended. Carriers of HBV who require treatment with infliximab should be closely </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">monitored for signs and symptoms of active HBV infection throughout therapy and for several months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">following termination of therapy. Adequate data of treating patients who are carriers of HBV with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antiviral therapy in conjunction with TNF-antagonist therapy to prevent HBV reactivation are not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available. In patients who develop HBV reactivation, infliximab should be stopped and effective </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antiviral therapy with appropriate supportive treatment should be initiated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">10 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatobiliary events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cases of jaundice and non-infectious hepatitis, some with features of autoimmune hepatitis, have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed in the post-marketing experience of infliximab. Isolated cases of liver failure resulting in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">liver transplantation or death have occurred. Patients with symptoms or signs of liver dysfunction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be evaluated for evidence of liver injury. If jaundice and/or ALT elevations </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 times the upper </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">limit of normal develop(s), infliximab should be discontinued, and a thorough investigation of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abnormality should be undertaken. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Concurrent administration of TNF-alpha inhibitor and anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Serious infections and neutropenia were seen in clinical studies with concurrent use of anakinra and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">another TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-blocking agent, etanercept, with no added clinical benefit compared to etanercept alone. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Because of the nature of the adverse reactions seen with combination of etanercept and anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapy, similar toxicities may also result from the combination of anakinra and other TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-blocking </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">agents. Therefore, the combination of infliximab and anakinra is not recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Concurrent administration of TNF-alpha inhibitor and abatacept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies concurrent administration of TNF-antagonists and abatacept has been associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with an increased risk of infections including serious infections compared to TNF-antagonists alone, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">without increased clinical benefit. The combination of infliximab and abatacept is not recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Concurrent administration with other biological therapeutics </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is insufficient information regarding the concomitant use of infliximab with other biological </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapeutics used to treat the same conditions as infliximab. The concomitant use of infliximab with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">these biologics is not recommended because of the possibility of an increased risk of infection, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">other potential pharmacological interactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Switching between biological DMARDs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Care should be taken and patients should continue to be monitored when switching from one biologic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to another, since overlapping biological activity may further increase the risk for adverse reactions, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">including infection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vaccinations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is recommended that patients, if possible, be brought up to date with all vaccinations in agreement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with current vaccination guidelines prior to initiating Remsima therapy. Patients on infliximab may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receive concurrent vaccinations, except for live vaccines (see sections 4.5 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a subset of 90 adult patients with rheumatoid arthritis from the ASPIRE study a similar proportion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of patients in each treatment group (methotrexate plus: placebo [n = 17], 3 mg/kg [n = 27] or 6 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab [n = 46]) mounted an effective two-fold increase in titers to a polyvalent pneumococcal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vaccine, indicating that infliximab did not interfere with T-cell independent humoral immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">responses. However, studies from the published literature in various indications (e.g. rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthritis, psoriasis, Crohn&#x2019;s disease) suggest that non-live vaccinations received during treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anti-TNF therapies, including infliximab may elicit a lower immune response than in patients not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receiving anti-TNF therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Live vaccines/therapeutic infectious agents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients receiving anti-TNF therapy, limited data are available on the response to vaccination with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">live vaccines or on the secondary transmission of infection by live vaccines. Use of live vaccines can </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:757pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">result in clinical infections, including disseminated infections. The concurrent administration of live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:770pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vaccines with infliximab is not recommended. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">11 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infant exposure </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In infants exposed </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> to infliximab, fatal outcome due to disseminated Bacillus Calmette-Gu&#xe9;rin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(BCG) infection has been reported following administration of BCG vaccine after birth. A twelve </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">month waiting period following birth is recommended before the administration of live vaccines to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infants exposed </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to infliximab. If infant infliximab serum levels are undetectable or infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration was limited to the first trimester of pregnancy, administration of a live vaccine might be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considered at an earlier timepoint if there is a clear clinical benefit for the individual infant (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infant exposure via breast milk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Administration of a live vaccine to a breastfed infant while the mother is receiving infliximab is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended unless infant infliximab serum levels are undetectable (see section 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Therapeutic infectious agents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Other uses of therapeutic infectious agents such as live attenuated bacteria (e.g., BCG bladder </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">instillation for the treatment of cancer) could result in clinical infections, including disseminated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infections. It is recommended that therapeutic infectious agents not be given concurrently with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Autoimmune processes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The relative deficiency of TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> caused by anti-TNF therapy may result in the initiation of an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">autoimmune process. If a patient develops symptoms suggestive of a lupus-like syndrome following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment with infliximab and is positive for antibodies against double-stranded DNA, further </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment with infliximab must not be given (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Neurological events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Use of TNF-blocking agents, including infliximab, has been associated with cases of new onset or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exacerbation of clinical symptoms and/or radiographic evidence of central nervous system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">demyelinating disorders, including multiple sclerosis, and peripheral demyelinating disorders, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">including Guillain-Barr&#xe9; syndrome. In patients with pre-existing or recent onset of demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disorders, the benefits and risks of anti-TNF treatment should be carefully considered before initiation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of infliximab therapy. Discontinuation of infliximab should be considered if these disorders develop. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the controlled portions of clinical studies of TNF-blocking agents, more cases of malignancies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">including lymphoma have been observed among patients receiving a TNF blocker compared with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">control patients. During clinical studies of infliximab across all approved indications the incidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lymphoma in infliximab-treated patients was higher than expected in the general population, but the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occurrence of lymphoma was rare. In the post-marketing setting, cases of leukaemia have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reported in patients treated with a TNF-antagonist. There is an increased background risk for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lymphoma and leukaemia in rheumatoid arthritis patients with long-standing, highly active, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inflammatory disease, which complicates risk estimation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In an exploratory clinical study evaluating the use of infliximab in patients with moderate to severe </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chronic obstructive pulmonary disease (COPD), more malignancies were reported in infliximab-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treated patients compared with control patients. All patients had a history of heavy smoking. Caution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be exercised in considering treatment of patients with increased risk for malignancy due to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">heavy smoking. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:732pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">With the current knowledge, a risk for the development of lymphomas or other malignancies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:757pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients treated with a TNF-blocking agent cannot be excluded (see section 4.8). Caution should be </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exercised when considering TNF-blocking therapy for patients with a history of malignancy or when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considering continuing treatment in patients who develop a malignancy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Caution should also be exercised in patients with psoriasis and a medical history of extensive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunosuppressant therapy or prolonged PUVA treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">22 years of age) treated with TNF-</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blocking agents (initiation of therapy &#x2264;18</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> years of age), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab in the post-marketing setting. Approximately half the cases were lymphomas. The other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cases represented a variety of different malignancies and included rare malignancies usually associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with immunosuppression. A risk for the development of malignancies in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">TNF-blockers cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treated with TNF-blocking agents including infliximab. This rare type of T-cell lymphoma has a very </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aggressive disease course and is usually fatal. Almost all patients had received treatment with AZA or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6-MP concomitantly with or immediately prior to a TNF-blocker. The vast majority of infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cases have occurred in patients with Crohn&#x2019;s disease or ulcerative colitis and most were reported in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adolescent or young adult males. The potential risk with the combination of AZA or 6-MP and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab should be carefully considered. A risk for the development for hepatosplenic T-cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lymphoma in patients treated with infliximab cannot be excluded (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapy, including infliximab (see section 4.8). Periodic skin examination is recommended, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">particularly for patients with risk factors for skin cancer. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A population-based retrospective cohort study using data from Swedish national health registries </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">found an increased incidence of cervical cancer in women with rheumatoid arthritis treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab compared to biologics-na&#xef;ve patients or the general population, including those over </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">60 years of age. Periodic screening should continue in women treated with infliximab, including those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">over 60 years of age. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">before therapy and throughout their disease course. This evaluation should include colonoscopy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">biopsies per local recommendations. Current data do not indicate that infliximab treatment influences </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the risk for developing dysplasia or colon cancer. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Since the possibility of increased risk of cancer development in patients with newly diagnosed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dysplasia treated with infliximab is not established, the risk and benefits of continued therapy to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">individual patients should be carefully considered by the clinician. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Heart failure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab should be used with caution in patients with mild heart failure (NYHA class I/II). Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be closely monitored and infliximab must not be continued in patients who develop new or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">worsening symptoms of heart failure (see sections 4.3 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Haematologic reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There have been reports of pancytopenia, leukopenia, neutropenia, and thrombocytopenia in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receiving TNF-blockers, including infliximab. All patients should be advised to seek immediate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fever, bruising, bleeding, pallor). Discontinuation of infliximab therapy should be considered in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with confirmed significant haematologic abnormalities. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:766pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">13 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Others </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is limited safety experience of infliximab treatment in patients who have undergone surgical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">procedures, including arthroplasty. The long half-life of infliximab should be taken into consideration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">if a surgical procedure is planned. A patient who requires surgery while on infliximab should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">closely monitored for infections, and appropriate actions should be taken. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Failure to respond to treatment for Crohn&#x2019;s disease may indicate the presence of a fixed fibrotic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">stricture that may require surgical treatment. There is no evidence to suggest that infliximab worsens </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or causes fibrotic strictures. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special populations  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Elderly </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The incidence of serious infections in infliximab-treated patients 65 years and older was greater than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in those under 65 years of age. Some of those had a fatal outcome. Particular attention regarding the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">risk for infection should be paid when treating the elderly (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Infections </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies, infections have been reported in a higher proportion of paediatric patients compared </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to adult patients (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Vaccinations </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is recommended that paediatric patients, if possible, be brought up to date with all vaccinations in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">agreement with current vaccination guidelines prior to initiating infliximab therapy. Paediatric patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">on infliximab may receive concurrent vaccinations, except for live vaccines (see sections 4.5 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">22 years of age) treated with TNF-</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blocking agents (initiation of therapy &#x2264;18</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> years of age), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab in the post-marketing setting. Approximately half the cases were lymphomas. The other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cases represented a variety of different malignancies and included rare malignancies usually associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with immunosuppression. A risk for the development of malignancies in children and adolescents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treated with TNF-blockers cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">TNF-blocking agents including infliximab. This rare type of T-cell lymphoma has a very aggressive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease course and is usually fatal. Almost all patients had received treatment with AZA or 6-MP </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitantly with or immediately prior to a TNF-blocker. The vast majority of infliximab cases have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occurred in patients with Crohn&#x2019;s disease or ulcerative colitis and most were reported in adolescent or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">young adult males. The potential risk with the combination of AZA or 6-MP and infliximab should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">carefully considered. A risk for the development for hepatosplenic T-cell lymphoma in patients treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with infliximab cannot be excluded (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sodium content </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially &#x2018;sodium-free&#x2019;. Remsima </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is however, diluted in sodium chloride 9 mg/ml (0.9%) solution for infusion. This should be taken into </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">consideration for patients on a controlled sodium diet (see section 6.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No interaction studies have been performed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">14 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In rheumatoid arthritis, psoriatic arthritis and Crohn&apos;s disease patients, there are indications that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant use of methotrexate and other immunomodulators reduces the formation of antibodies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">against infliximab and increases the plasma concentrations of infliximab. However, the results are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">uncertain due to limitations in the methods used for serum analyses of infliximab and antibodies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">against infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Corticosteroids do not appear to affect the pharmacokinetics of infliximab to a clinically relevant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">extent. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The combination of infliximab with other biological therapeutics used to treat the same conditions as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab, including anakinra and abatacept, is not recommended (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is recommended that live vaccines not be given concurrently with infliximab. It is also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended that live vaccines not be given to infants after </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> exposure to infliximab for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">12 months following birth. If infant infliximab serum levels are undetectable or infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration was limited to the first trimester of pregnancy, administration of a live vaccine might be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considered at an earlier timepoint if there is a clear clinical benefit for the individual infant (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Administration of a live vaccine to a breastfed infant while the mother is receiving infliximab is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended unless infant infliximab serum levels are undetectable (see sections 4.4 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is recommended that therapeutic infectious agents not be given concurrently with infliximab (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fertility, pregnancy and lactation </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Women of childbearing potential </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Women of childbearing potential should consider the use of adequate contraception to prevent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy and continue its use for at least 6 months after the last infliximab treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The moderate number of prospectively collected pregnancies exposed to infliximab resulting in live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">birth with known outcomes, including approximately 1,100 exposed during the first trimester, does not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">indicate an increase in the rate of malformation in the newborn.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on an observational study from Northern Europe, an increased risk (OR, 95% CI; p-value) for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C-section (1.50, 1.14-1.96; p = 0.0032), preterm birth (1.48, 1.05-2.09; p = 0.024), small for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">gestational age (2.79, 1.54-5.04; p = 0.0007), and low birth weight (2.03, 1.41-2.94; p = 0.0002) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed in women exposed during pregnancy to infliximab (with or without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunomodulators/corticosteroids, 270 pregnancies) as compared to women exposed to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunomodulators and/or corticosteroids only (6,460 pregnancies). The potential contribution of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exposure to infliximab and/or the severity of the underlying disease in these outcomes remains </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">unclear. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Due to its inhibition of TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, infliximab administered during pregnancy could affect normal immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">responses in the newborn. In a developmental toxicity study conducted in mice using an analogous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antibody that selectively inhibits the functional activity of mouse TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, there was no indication of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maternal toxicity, embryotoxicity or teratogenicity (see section 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The available clinical experience is limited. Infliximab should only be used during pregnancy if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clearly needed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab crosses the placenta and has been detected in the serum of infants up to 12 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">following birth. After </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> exposure to infliximab, infants may be at increased risk of infection, </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">15 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">including serious disseminated infection that can become fatal. Administration of live vaccines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(e.g., BCG vaccine) to infants exposed to infliximab </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> is not recommended for 12 months after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">birth (see sections 4.4 and 4.5). If infant infliximab serum levels are undetectable or infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration was limited to the first trimester of pregnancy, administration of a live vaccine might be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considered at an earlier timepoint if there is a clear clinical benefit for the individual infant. Cases of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">agranulocytosis have also been reported (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Limited data from published literature indicate infliximab has been detected at low levels in human </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">milk at concentrations up to 5% of the maternal serum level. Infliximab has also been detected in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infant serum after exposure to infliximab via breast milk. While systemic exposure in a breastfed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infant is expected to be low because infliximab is largely degraded in the gastrointestinal tract, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration of live vaccines to a breastfed infant when the mother is receiving infliximab is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended unless infant infliximab serum levels are undetectable. Infliximab could be considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">for use during breast-feeding. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are insufficient preclinical data to draw conclusions on the effects of infliximab on fertility and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">general reproductive function (see section 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima may have a minor influence on the ability to drive and use machines. Dizziness may occur </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">following administration of infliximab (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Undesirable effects </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Summary of the safety profile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Upper respiratory tract infection was the most common adverse drug reaction (ADR) reported in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical trials, occurring in 25.3% of infliximab-treated patients compared with 16.5% of control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients. The most serious ADRs associated with the use of TNF blockers that have been reported for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab include HBV reactivation, CHF (congestive heart failure), serious infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sepsis, opportunistic infections and TB), serum sickness (delayed hypersensitivity reactions), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">haematologic reactions, systemic lupus erythematosus/lupus-like syndrome, demyelinating disorders, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatobiliary events, lymphoma, HSTCL, leukaemia, Merkel cell carcinoma, melanoma, paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">malignancy, sarcoidosis/sarcoid-like reaction, intestinal or perianal abscess (in Crohn&#x2019;s disease), and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serious infusion reactions (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tabulated list of adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Table 1 lists the ADRs based on experience from clinical studies as well as adverse reactions, some </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with fatal outcome, reported from post-marketing experience. Within the organ system classes, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions are listed under headings of frequency using the following categories: very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10); common (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/100 to &lt; </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10); uncommon (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/1,000 to &lt; </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/100); rare (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/10,000 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). Within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">each frequency grouping, undesirable effects are presented in order of decreasing seriousness. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">16 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:79pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:79pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adverse reactions in clinical studies and from post-marketing experience</span></b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Infections and infestations </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Viral infection (e.g. influenza, herpes virus infection). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bacterial infections (e.g. sepsis, cellulitis, abscess).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tuberculosis, fungal infections (e.g. candidiasis, onychomycosis). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Meningitis, opportunistic infections (such as invasive fungal infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[pneumocystosis, histoplasmosis, aspergillosis, coccidioidomycosis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cryptococcosis, blastomycosis], bacterial infections [atypical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:178pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mycobacterial, listeriosis, salmonellosis], and viral infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[cytomegalovirus]), parasitic infections, hepatitis B reactivation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vaccine breakthrough infection (after </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exposure to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab)*. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Neoplasms benign, malignant and unspecified (including cysts and polyps) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lymphoma, non-Hodgkin&#x2019;s lymphoma, Hodgkin&#x2019;s disease, leukaemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">melanoma, cervical cancer. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatosplenic T-cell lymphoma (primarily in adolescents and young </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adult males with Crohn&#x2019;s disease and ulcerative colitis), Merkel cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">carcinoma, Kaposi&#x2019;s sarcoma. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Blood and lymphatic system disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Neutropenia, leukopenia, anaemia, lymphadenopathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Thrombocytopenia, lymphopenia, lymphocytosis.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agranulocytosis (including infants exposed </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to infliximab), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">thrombotic thrombocytopenic purpura, pancytopenia, haemolytic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaemia, idiopathic thrombocytopenic purpura. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Immune system disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Allergic respiratory symptom. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Anaphylactic reaction, lupus-like syndrome, serum sickness or serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sickness-like reaction. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Anaphylactic shock, vasculitis, sarcoid-like reaction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Metabolism and nutrition disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dyslipidaemia. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Psychiatric disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Depression, insomnia. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Amnesia, agitation, confusion, somnolence, nervousness. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Apathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nervous system disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Headache. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vertigo, dizziness, hypoaesthesia, paraesthesia. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Seizure, neuropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Transverse myelitis, central nervous system demyelinating disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(multiple sclerosis-like disease and optic neuritis), peripheral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">demyelinating disorders (such as Guillain-Barr&#xe9; syndrome, chronic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inflammatory demyelinating polyneuropathy and multifocal motor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">neuropathy). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cerebrovascular accidents in close temporal association with infusion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Eye disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Conjunctivitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Keratitis, periorbital oedema, hordeolum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Endophthalmitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Transient visual loss occurring during or within 2 hours of infusion </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">17 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Cardiac disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tachycardia, palpitation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cardiac failure (new onset or worsening), arrhythmia, syncope, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bradycardia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cyanosis, pericardial effusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Myocardial ischaemia/myocardial infarction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Vascular disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypotension, hypertension, ecchymosis, hot flush, flushing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:179pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:179pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Peripheral ischaemia, thrombophlebitis, haematoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Circulatory failure, petechia, vasospasm </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Respiratory, thoracic and mediastinal disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Upper respiratory tract infection, sinusitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lower respiratory tract infection (e.g. bronchitis, pneumonia), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dyspnoea, epistaxis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pulmonary oedema, bronchospasm, pleurisy, pleural effusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Interstitial lung disease (including rapidly progressive disease, lung </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fibrosis and pneumonitis) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Gastrointestinal disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Abdominal pain, nausea </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastrointestinal haemorrhage, diarrhoea, dyspepsia, gastroesophageal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reflux, constipation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Intestinal perforation, intestinal stenosis, diverticulitis, pancreatitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cheilitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatobiliary disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatic function abnormal, transaminases increased. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatitis, hepatocellular damage, cholecystitis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Autoimmune hepatitis, jaundice. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Liver failure. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Skin and subcutaneous tissue disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">New onset or worsening psoriasis including pustular psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(primarily palm &amp; soles), urticaria, rash, pruritus, hyperhidrosis, dry </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">skin, fungal dermatitis, eczema, alopecia. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bullous eruption, seborrhoea, rosacea, skin papilloma, hyperkeratosis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abnormal skin pigmentation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">multiforme, furunculosis, linear IgA bullous dermatosis (LABD), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">acute generalised exanthematous pustulosis (AGEP), lichenoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Worsening of symptoms of dermatomyositis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Musculoskeletal and connective tissue disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:207pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Arthralgia, myalgia, back pain. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal and urinary disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Urinary tract infection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pyelonephritis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Reproductive system and breast disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:207pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vaginitis. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">18 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">General disorders and administration site conditions </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infusion-related reaction, pain. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Chest pain, fatigue, fever, injection site reaction, chills, oedema. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:99pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:99pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Impaired healing. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Granulomatous lesion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Investigations </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Autoantibody positive. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Complement factor abnormal. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">* including bovine tuberculosis (disseminated BCG infection), see section 4.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Description of selected adverse drug reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infusion-related reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">An infusion-related reaction was defined in clinical studies as any adverse event occurring during an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion or within 1 hour after an infusion. In phase III clinical studies, 18% of infliximab-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients compared with 5% of placebo-treated patients experienced an infusion-related reaction. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Overall, a higher proportion of patients receiving infliximab monotherapy experienced an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion-related reaction compared to patients receiving infliximab with concomitant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunomodulators. Approximately 3% of patients discontinued treatment due to infusion-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions and all patients recovered with or without medical therapy. Of infliximab-treated patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">who had an infusion reaction during the induction period, through week 6, 27% experienced an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion reaction during the maintenance period, week 7 through week 54. Of patients who did not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have an infusion reaction during the induction period, 9% experienced an infusion reaction during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintenance period.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:10.56pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:10.56pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a clinical study of patients with rheumatoid arthritis (ASPIRE), infusions were to be administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">over 2 hours for the first 3 infusions. The duration of subsequent infusions could be shortened to not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">less than 40 minutes in patients who did not experience serious infusion reactions. In this trial, sixty </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">six percent of the patients (686 out of 1,040) received at least one shortened infusion of 90 minutes or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">less and 44% of the patients (454 out of 1,040) received at least one shortened infusion of 60 minutes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or less. Of the infliximab-treated patients who received at least one shortened infusion, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion-related reactions occurred in 15% of patients and serious infusion reactions occurred in 0.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a clinical study of patients with Crohn&#x2019;s disease (SONIC), infusion-related reactions occurred in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">16.6% (27/163) of patients receiving infliximab monotherapy, 5% (9/179) of patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab in combination with AZA, and 5.6% (9/161) of patients receiving AZA monotherapy. One </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serious infusion reaction (&lt;1%) occurred in a patient on infliximab monotherapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In post-marketing experience, cases of anaphylactic-like reactions, including laryngeal/pharyngeal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">oedema and severe bronchospasm, and seizure have been associated with infliximab administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 4.4). Cases of transient visual loss occurring during or within 2 hours of infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion have been reported. Events (some fatal) of myocardial ischaemia/infarction and arrhythmia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have been reported, some in close temporal association with infusion of infliximab; cerebrovascular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">accidents have also been reported in close temporal association with infusion of infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infusion reactions following re-administration of infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A clinical study in patients with moderate to severe psoriasis was designed to assess the efficacy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">safety of long-term maintenance therapy versus re-treatment with an induction regimen of infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(maximum of four infusions at 0, 2, 6 and 14 weeks) following disease flare. Patients did not receive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">any concomitant immunosuppressant therapy. In the re-treatment arm, 4% (8/219) of patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">experienced a serious infusion reaction versus &lt;1% (1/222) on maintenance therapy. The majority of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serious infusion reactions occurred during the second infusion at week 2. The interval between the last </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">19 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintenance dose and the first re-induction dose ranged from 35-231 days. Symptoms included, but </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were not limited to, dyspnoea, urticaria, facial oedema, and hypotension. In all cases, infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment was discontinued and/or other treatment instituted with complete resolution of signs and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">symptoms. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Delayed hypersensitivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies delayed hypersensitivity reactions have been uncommon and have occurred after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab-free intervals of less than 1 year. In the psoriasis studies, delayed hypersensitivity reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occurred early in the treatment course. Signs and symptoms included myalgia and/or arthralgia with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fever and/or rash, with some patients experiencing pruritus, facial, hand or lip oedema, dysphagia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">urticaria, sore throat and headache. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are insufficient data on the incidence of delayed hypersensitivity reactions after infliximab-free </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">intervals of more than 1 year but limited data from clinical studies suggest an increased risk for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">delayed hypersensitivity with increasing infliximab-free interval (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a 1-year clinical study with repeated infusions in patients with Crohn&apos;s disease (ACCENT I study), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the incidence of serum sickness-like reactions was 2.4%. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Immunogenicity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients who developed antibodies to infliximab were more likely (approximately 2-3 fold) to develop </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion-related reactions. Use of concomitant immunosuppressant agents appeared to reduce the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">frequency of infusion-related reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies using single and multiple infliximab doses ranging from 1 to 20 mg/kg, antibodies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to infliximab were detected in 14% of patients with any immunosuppressant therapy, and in 24% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients without immunosuppressant therapy. In rheumatoid arthritis patients who received the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended repeated treatment dose regimens with methotrexate, 8% of patients developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antibodies to infliximab. In psoriatic arthritis patients who received 5 mg/kg with and without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">methotrexate, antibodies occurred overall in 15% of patients (antibodies occurred in 4% of patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receiving methotrexate and in 26% of patients not receiving methotrexate at baseline). In Crohn&apos;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease patients who received maintenance treatment, antibodies to infliximab occurred overall in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.3% of patients receiving immunosuppressants and in 13.3% of patients not receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunosuppressants. The antibody incidence was 2-3 fold higher for patients treated episodically. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Due to methodological limitations, a negative assay did not exclude the presence of antibodies to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab. Some patients who developed high titres of antibodies to infliximab had evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduced efficacy. In psoriasis patients treated with infliximab as a maintenance regimen in the absence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of concomitant immunomodulators, approximately 28% developed antibodies to infliximab (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4: &quot;Infusion reactions and hypersensitivity&quot;). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tuberculosis, bacterial infections, including sepsis and pneumonia, invasive fungal, viral, and other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">opportunistic infections have been observed in patients receiving infliximab. Some of these infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have been fatal; the most frequently reported opportunistic infections with a mortality rate of &gt;5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">include pneumocystosis, candidiasis, listeriosis and aspergillosis (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies 36% of infliximab-treated patients were treated for infections compared with 25% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In rheumatoid arthritis clinical studies, the incidence of serious infections including pneumonia was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">higher in infliximab plus methotrexate-treated patients compared with methotrexate alone especially at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">doses of 6 mg/kg or greater (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In post-marketing spontaneous reporting, infections are the most common serious adverse reaction. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Some of the cases have resulted in a fatal outcome. Nearly 50% of reported deaths have been </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">associated with infection. Cases of tuberculosis, sometimes fatal, including miliary tuberculosis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tuberculosis with extra-pulmonary location have been reported (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies with infliximab in which 5,780 patients were treated, representing 5,494 patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">years, 5 cases of lymphomas and 26 non-lymphoma malignancies were detected as compared with no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lymphomas and 1 non-lymphoma malignancy in 1,600 placebo-treated patients representing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">941 patient years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In long-term safety follow-up of clinical studies with infliximab of up to 5 years, representing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6,234 patients-years (3,210 patients), 5 cases of lymphoma and 38 cases of non-lymphoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">malignancies were reported. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cases of malignancies, including lymphoma, have also been reported in the post-marketing setting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In an exploratory clinical study involving patients with moderate to severe COPD who were either </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">current smokers or ex-smokers, 157 adult patients were treated with infliximab at doses similar to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">those used in rheumatoid arthritis and Crohn&#x2019;s disease. Nine of these patients developed malignancies, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">including 1 lymphoma. The median duration of follow-up was 0.8 years (incidence 5.7% [95% CI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2.65%-10.6%]. There was one reported malignancy amongst 77 control patients (median duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">follow-up 0.8 years; incidence 1.3% [95% CI 0.03%-7.0%]). The majority of the malignancies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">developed in the lung or head and neck. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A population-based retrospective cohort study found an increased incidence of cervical cancer in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">women with rheumatoid arthritis treated with infliximab compared to biologics-na&#xef;ve patients or the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">general population, including those over 60 years of age (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In addition, post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treated with infliximab with the vast majority of cases occurring in Crohn&#x2019;s disease and ulcerative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">colitis, and most of whom were adolescent or young adult males (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Heart failure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a Phase II study aimed at evaluating infliximab in CHF, higher incidence of mortality due to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">worsening of heart failure were seen in patients treated with infliximab, especially those treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the higher dose of 10 mg/kg (i.e. twice the maximum approved dose). In this study 150 patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">NYHA Class III-IV CHF (left ventricular ejection fraction </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">35%) were treated with 3 infusions of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab 5 mg/kg, 10 mg/kg, or placebo over 6 weeks. At 38 weeks, 9 of 101 patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab (2 at 5 mg/kg and 7 at 10 mg/kg) died compared to one death among the 49 patients on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There have been post-marketing reports of worsening heart failure, with and without identifiable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">precipitating factors, in patients taking infliximab. There have also been post-marketing reports of new </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">onset heart failure, including heart failure in patients without known pre-existing cardiovascular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease. Some of these patients have been under 50 years of age. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatobiliary events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies, mild or moderate elevations of ALT and AST have been observed in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receiving infliximab without progression to severe hepatic injury. Elevations of ALT </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 x Upper </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Limit of Normal (ULN) have been observed (see Table 2). Elevations of aminotransferases were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed (ALT more common than AST) in a greater proportion of patients receiving infliximab than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in controls, both when infliximab was given as monotherapy and when it was used in combination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with other immunosuppressive agents. Most aminotransferase abnormalities were transient; however, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a small number of patients experienced more prolonged elevations. In general, patients who developed </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">21 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ALT and AST elevations were asymptomatic, and the abnormalities decreased or resolved with either </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">continuation or discontinuation of infliximab, or modification of concomitant therapy. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">post-marketing surveillance, cases of jaundice and hepatitis, some with features of autoimmune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatitis, have been reported in patients receiving infliximab (see section 4.4).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:137pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Proportion of patients with increased ALT activity in clinical studies</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Indication </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Number of patients</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:248pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Median follow-up </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:273pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(wks)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">4</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:367pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;3 x ULN</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;5 x ULN</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:141pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo infliximab placebo infliximab placebo infliximab placebo infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthritis</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:141pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">375 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:186pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1,087 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:242pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">58.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:287pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">58.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:389pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:446pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.8% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:491pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Crohn&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:141pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">324 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:186pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1,034 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:242pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">53.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:287pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">54.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2.2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:389pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:446pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:491pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Crohn&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:141pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:186pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">139 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:242pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:287pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">53.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:389pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:446pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:491pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ulcerative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">colitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:141pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">242 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:186pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">482 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:242pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">30.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:287pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">30.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:389pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:446pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:491pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ulcerative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">colitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:141pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:186pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">60 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:242pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:287pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">49.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:389pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:446pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:491pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ankylosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">spondylitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:141pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">76 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:186pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">275 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:242pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">24.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:287pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">101.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:389pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:446pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:491pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:141pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">98 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:186pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">191 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:242pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">18.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:287pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">39.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:389pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.8% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:446pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:491pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2.1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:141pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">281 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:186pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1,175 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:242pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">16.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:287pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:389pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7.7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:446pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:491pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 Placebo patients received methotrexate while infliximab patients received both infliximab and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">methotrexate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 Placebo patients in the 2 Phase III studies in Crohn&#x2019;s disease, ACCENT I and ACCENT II, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">received an initial dose of 5 mg/kg infliximab at study start and were on placebo in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintenance phase. Patients who were randomised to the placebo maintenance group and then later </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">crossed over to infliximab are included in the infliximab group in the ALT analysis. In the Phase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">IIIb trial in Crohn&#x2019;s disease, SONIC, placebo patients received AZA 2.5 mg/kg/day as active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">control in addition to placebo infliximab infusions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 Number of patients evaluated for ALT. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4 Median follow-up is based on patients treated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Antinuclear antibodies (ANA)/Anti-double-stranded DNA (dsDNA) antibodies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Approximately half of infliximab-treated patients in clinical studies who were ANA negative at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline developed a positive ANA during the study compared with approximately one fifth of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo-treated patients. Anti-dsDNA antibodies were newly detected in approximately 17% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab-treated patients compared with 0% of placebo-treated patients. At the last evaluation, 57% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of infliximab-treated patients remained anti-dsDNA positive. Reports of lupus and lupus-like </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">syndromes, however, remain uncommon (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Juvenile rheumatoid arthritis patients </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab was studied in a clinical study in 120 patients (age range: 4-17 years old) with active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">juvenile rheumatoid arthritis despite methotrexate. Patients received 3 or 6 mg/kg infliximab as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3-dose induction regimen (weeks 0, 2, 6 or weeks 14, 16, 20, respectively) followed by maintenance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapy every 8 weeks, in combination with methotrexate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">22 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Infusion reactions </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infusion reactions occurred in 35% of patients with juvenile rheumatoid arthritis receiving 3 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared with 17.5% of patients receiving 6 mg/kg. In the 3 mg/kg infliximab group, 4 out of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">60 patients had a serious infusion reaction and 3 patients reported a possible anaphylactic reaction (2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of which were among the serious infusion reactions). In the 6 mg/kg group, 2 out of 57 patients had a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serious infusion reaction, one of whom had a possible anaphylactic reaction (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Immunogenicity </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Antibodies to infliximab developed in 38% of patients receiving 3 mg/kg compared with 12% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients receiving 6 mg/kg. The antibody titres were notably higher for the 3 mg/kg compared to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 mg/kg group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Infections </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infections occurred in 68% (41/60) of children receiving 3 mg/kg over 52 weeks, 65% (37/57) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">children receiving infliximab 6 mg/kg over 38 weeks and 47% (28/60) of children receiving placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">over 14 weeks (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric Crohn&#x2019;s disease patients </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The following adverse reactions were reported more commonly in paediatric Crohn&#x2019;s disease patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the REACH study (see section 5.1) than in adult Crohn&#x2019;s disease patients: anaemia (10.7%), blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in stool (9.7%), leukopenia (8.7%), flushing (8.7%), viral infection (7.8%), neutropenia (6.8%), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bacterial infection (5.8%), and respiratory tract allergic reaction (5.8%). In addition, bone fracture </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(6.8%) was reported, however, a causal association has not been established. Other special </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considerations are discussed below. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Infusion</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">related reactions </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In REACH, 17.5% of randomised patients experienced 1 or more infusion reactions. There were no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serious infusion reactions, and 2 subjects in REACH had non-serious anaphylactic reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Immunogenicity </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Antibodies to infliximab were detected in 3 (2.9%) paediatric patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Infections </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the REACH study, infections were reported in 56.3% of randomised subjects treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab. Infections were reported more frequently for subjects who received q8 week as opposed to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q12 week infusions (73.6% and 38.0%, respectively), while serious infections were reported for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 subjects in the q8 week and 4 subjects in the q12 week maintenance treatment group. The most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">commonly reported infections were upper respiratory tract infection and pharyngitis, and the most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">commonly reported serious infection was abscess. Three cases of pneumonia (1 serious) and 2 cases of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">herpes zoster (both non-serious) were reported. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric ulcerative colitis patients </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Overall, the adverse reactions reported in the paediatric ulcerative colitis trial (C0168T72) and adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ulcerative colitis (ACT 1 and ACT 2) studies were generally consistent. In C0168T72, the most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">common adverse reactions were upper respiratory tract infection, pharyngitis, abdominal pain, fever, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and headache. The most common adverse event was worsening of ulcerative colitis, the incidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">which was higher in patients on the q12 week vs. the q8 week dosing regimen. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Infusion</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">related reactions </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Overall, 8 (13.3%) of 60 treated patients experienced one or more infusion reactions, with 4 of 22 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(18.2%) in the q8 week and 3 of 23 (13.0%) in the q12 week treatment maintenance group. No serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion reactions were reported. All infusion reactions were mild or moderate in intensity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Immunogenicity </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Antibodies to infliximab were detected in 4 (7.7%) patients through week 54. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">23 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Infections </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infections were reported in 31 (51.7%) of 60 treated patients in C0168T72 and 22 (36.7%) required </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">oral or parenteral antimicrobial treatment. The proportion of patients with infections in C0168T72 was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">similar to that in the paediatric Crohn&#x2019;s disease study (REACH) but higher than the proportion in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adults ulcerative colitis studies (ACT 1 and ACT 2). The overall incidence of infections in C0168T72 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was 13/22 (59%) in the every 8 week maintenance treatment group and 14/23 (60.9%) in the every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">12 week maintenance treatment group. Upper respiratory tract infection (7/60 [12%]) and pharyngitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(5/60 [8%]) were the most frequently reported respiratory system infections. Serious infections were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reported in 12% (7/60) of all treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In this study, there were more patients in the 12 to 17 year age group than in the 6 to 11 year age group </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(45/60 [75.0%]) vs.15/60 [25.0%]). While the numbers of patients in each subgroup are too small to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">make any definitive conclusions about the effect of age on safety events, there were higher proportions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of patients with serious adverse events and discontinuation due to adverse events in the younger age </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group than in the older age group. While the proportion of patients with infections was also higher in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the younger age group, for serious infections, the proportions were similar in the two age groups. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Overall proportions of adverse events and infusion reactions were similar between the 6 to 11 and 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to 17 year age groups. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Post-marketing experience </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Post-marketing spontaneous serious adverse reactions with infliximab in the paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have included malignancies including hepatosplenic T-cell lymphomas, transient hepatic enzyme </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abnormalities, lupus-like syndromes, and positive auto-antibodies (see sections 4.4 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Other special populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Elderly </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In rheumatoid arthritis clinical studies, the incidence of serious infections was greater in infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">plus methotrexate-treated patients 65 years and older (11.3%) than in those under 65 years of age </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(4.6%). In patients treated with methotrexate alone, the incidence of serious infections was 5.2% in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients 65 years and older compared to 2.7% in patients under 65 (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting of suspected adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">listed in </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">Appendix V</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Overdose </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No case of overdose has been reported. Single doses up to 20 mg/kg have been administered without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">toxic effects. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacodynamic properties</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacotherapeutic group: immunosuppressants, tumour necrosis factor alpha (TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ATC code: L04AB02 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is a biosimilar medicinal product. Detailed information is available on the website of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:766pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">European Medicines Agency </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">24 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mechanism of action </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">soluble and transmembrane forms of TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">but not to lymphotoxin &#x3b1; (TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b2;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacodynamic effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab inhibits the functional activity of TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> in a wide variety of </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bioassays. Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">prevented disease in transgenic mice that develop polyarthritis as a result of constitutive expression of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">human TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and when administered after disease onset, it allowed eroded joints to heal. </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab rapidly forms stable complexes with human TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, a process that parallels the loss of TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bioactivity.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Elevated concentrations of TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> have been found in the joints of rheumatoid arthritis patients and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">correlate with elevated disease activity. In rheumatoid arthritis, treatment with infliximab reduced </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infiltration of inflammatory cells into inflamed areas of the joint as well as expression of molecules </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mediating cellular adhesion, chemoattraction and tissue degradation. After infliximab treatment, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients exhibited decreased levels of serum interleukin 6 (IL-6) and C-reactive protein (CRP), and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increased haemoglobin levels in rheumatoid arthritis patients with reduced haemoglobin levels, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared with baseline. Peripheral blood lymphocytes further showed no significant decrease in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">number or in proliferative responses to </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> mitogenic stimulation when compared with untreated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients&#x2019; cells. In psoriasis patients, treatment with infliximab resulted in decreases in epidermal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inflammation and normalisation of keratinocyte differentiation in psoriatic plaques. In psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthritis, short term treatment with infliximab reduced the number of T-cells and blood vessels in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">synovium and psoriatic skin. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Histological evaluation of colonic biopsies, obtained before and 4 weeks after administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab, revealed a substantial reduction in detectable TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. Infliximab treatment of Crohn&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease patients was also associated with a substantial reduction of the commonly elevated serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inflammatory marker, CRP. Total peripheral white blood cell counts were minimally affected in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab-treated patients, although changes in lymphocytes, monocytes and neutrophils reflected </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">shifts towards normal ranges. Peripheral blood mononuclear cells (PBMC) from infliximab-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients showed undiminished proliferative responsiveness to stimuli compared with untreated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients, and no substantial changes in cytokine production by stimulated PBMC were observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">following treatment with infliximab. Analysis of lamina propria mononuclear cells obtained by biopsy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of the intestinal mucosa showed that infliximab treatment caused a reduction in the number of cells </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">capable of expressing TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and interferon </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x3b3;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. Additional histological studies provided evidence that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment with infliximab reduces the infiltration of inflammatory cells into affected areas of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">intestine and the presence of inflammation markers at these sites. Endoscopic studies of intestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mucosa have shown evidence of mucosal healing in infliximab-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical efficacy and safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adult rheumatoid arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of infliximab was assessed in two multicentre, randomised, double-blind, pivotal clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies: ATTRACT and ASPIRE. In both studies concurrent use of stable doses of folic acid, oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">corticosteroids (&#x2264;10</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> mg/day) and/or non-steroidal anti-inflammatory drugs (NSAIDs) was permitted. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The primary endpoints were the reduction of signs and symptoms as assessed by the American </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">College of Rheumatology criteria (ACR20 for ATTRACT, landmark ACR-N for ASPIRE), the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">prevention of structural joint damage, and the improvement in physical function. A reduction in signs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and symptoms was defined to be at least a 20% improvement (ACR20) in both tender and swollen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">joint counts, and in 3 of the following 5 criteria: (1) evaluator&#x2019;s global assessment, (2) patient&#x2019;s global </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">assessment, (3) functional/disability measure, (4) visual analogue pain scale and (5) erythrocyte </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sedimentation rate or C-reactive protein. ACR-N uses the same criteria as the ACR20, calculated by </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">25 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">taking the lowest percent improvement in swollen joint count, tender joint count, and the median of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the remaining 5 components of the ACR response. Structural joint damage (erosions and joint space </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">narrowing) in both hands and feet was measured by the change from baseline in the total van der </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Heijde-modified Sharp score (0-440). The Health Assessment Questionnaire (HAQ; scale 0-3) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">used to measure patients&#x2019; average change from baseline scores over time, in physical function. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The ATTRACT study evaluated responses at 30, 54 and 102 weeks in a placebo-controlled study of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">428 patients with active rheumatoid arthritis despite treatment with methotrexate. Approximately 50% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of patients were in functional Class III. Patients received placebo, 3 mg/kg or 10 mg/kg infliximab at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weeks 0, 2 and 6, and then every 4 or 8 weeks thereafter. All patients were on stable methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">doses (median 15 mg/wk) for 6 months prior to enrolment and were to remain on stable doses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">throughout the study. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Results from week 54 (ACR20, total van der Heijde-modified Sharp score and HAQ) are shown in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Table 3. Higher degrees of clinical response (ACR50 and ACR70) were observed in all infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">groups at 30 and 54 weeks compared with methotrexate alone. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A reduction in the rate of the progression of structural joint damage (erosions and joint space </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">narrowing) was observed in all infliximab groups at 54 weeks (Table 3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The effects observed at 54 weeks were maintained through 102 weeks. Due to a number of treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">withdrawals, the magnitude of the effect difference between infliximab and the methotrexate alone </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group cannot be defined. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ACR20, Structural Joint Damage and Physical Function at week 54, ATTRACT</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:363pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Control</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q 8 wks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q 4 wks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q 8 wks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q 4 wks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">All </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with ACR20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response/Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">evaluated (%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">15/88 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(17%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">36/86 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(42%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">41/86 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(48%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">51/87 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(59%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">48/81 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(59%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">176/340 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(52%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Total score</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">d</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> (van der Heijde-modified Sharp score) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Change from baseline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Mean &#xb1; SD</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">c</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7.0 &#xb1; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:250pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.3 &#xb1; 6.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:304pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.6 &#xb1; 8.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:359pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.2 &#xb1; 3.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:416pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.7 &#xb1; 3.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:473pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.6 &#xb1; 5.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Interquartile range) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.5,9.7) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-1.5,3.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-2.5,3.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-1.5,2.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-3.0,1.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-1.8,2.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">deterioration/patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">evaluated (%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">c</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">13/64 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(20%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">34/71 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(48%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">35/71 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(49%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">37/77 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(48%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">44/66 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(67%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">150/285 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(53%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HAQ change from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline over time</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">e</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(patients evaluated) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">87 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">86 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">85 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">87 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">81 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">339 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mean &#xb1; SD</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">c</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.2 &#xb1; 0.3  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.4 &#xb1; 0.3  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.5 &#xb1; 0.4  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.5 &#xb1; 0.5  0.4 &#xb1; 0.4  0.4 &#xb1; 0.4  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a control = All patients had active RA despite treatment with stable methotrexate doses for 6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">months prior to enrolment and were to remain on stable doses throughout the study. Concurrent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">use of stable doses of oral corticosteroids (&#x2264;10</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> mg/day) and/or NSAIDs was permitted, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">folate supplementation was given. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">b all infliximab doses given in combination with methotrexate and folate with some on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">corticosteroids and/or NSAIDs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">c p &lt;0.001, for each infliximab treatment group vs. control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">d greater values indicate more joint damage. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">e HAQ = Health Assessment Questionnaire; greater values indicate less disability. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The ASPIRE study evaluated responses at 54 weeks in 1,004 methotrexate naive patients with early </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2264;3</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> years disease duration, median 0.6 years) active rheumatoid arthritis (median swollen and tender </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">joint count of 19 and 31, respectively). All patients received methotrexate (optimised to 20 mg/wk by </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">26 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 8) and either placebo, 3 mg/kg or 6 mg/kg infliximab at weeks 0, 2, and 6 and every 8 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">thereafter. Results from week 54 are shown in Table 4. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After 54 weeks of treatment, both doses of infliximab + methotrexate resulted in statistically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significantly greater improvement in signs and symptoms compared to methotrexate alone as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">measured by the proportion of patients achieving ACR20, 50 and 70 responses. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In ASPIRE, more than 90% of patients had at least two evaluable X-rays. Reduction in the rate of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">progression of structural damage was observed at weeks 30 and 54 in the infliximab + methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">groups compared to methotrexate alone. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:94pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ACRn, Structural Joint Damage and Physical Function at week 54, ASPIRE</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:377pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab + MTX </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">+ MTX </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:321pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:391pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Combined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Subjects randomised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">282 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:321pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">359 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:391pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">363 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">722 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Percentage ACR improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mean &#xb1; SD</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">24.8 &#xb1; 59.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:321pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">37.3 &#xb1; 52.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:391pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">42.0 &#xb1; 47.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">39.6 &#xb1; 50.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Change from baseline in total van der Heijde-modified Sharp score</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mean &#xb1; SD</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.70 &#xb1; 9.61 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:321pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.42 &#xb1; 5.82 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:391pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.51 &#xb1; 5.55 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.46 &#xb1; 5.68 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.43 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:321pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.00 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:391pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.00 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.00 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Improvement from baseline in HAQ averaged over time from week 30 to week 54</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">c</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mean &#xb1; SD</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">d</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.68 &#xb1; 0.63 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:321pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.80 &#xb1; 0.65 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:391pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.88 &#xb1; 0.65 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.84 &#xb1; 0.65 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> p &lt;0.001, for each infliximab treatment group vs control. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">b </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">greater values indicate more joint damage. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">c </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HAQ = Health Assessment Questionnaire; greater values indicate less disability. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">d </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">p = 0.030 and &lt;0.001 for the 3 mg/kg and 6 mg/kg treatment groups respectively vs. placebo + </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">MTX. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Data to support dose titration in rheumatoid arthritis come from ATTRACT, ASPIRE and the START </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">study. START was a randomised, multicentre, double-blind, 3-arm, parallel-group safety study. In one </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of the study arms (group 2, n=329), patients with an inadequate response were allowed to dose titrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with 1.5 mg/kg increments from 3 up to 9 mg/kg. The majority (67%) of these patients did not require </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">any dose titration. Of the patients who required a dose titration, 80% achieved clinical response and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the majority (64%) of these required only one adjustment of 1.5 mg/kg. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adult Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Induction treatment in moderately to severely active Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of a single dose treatment with infliximab was assessed in 108 patients with active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Crohn&#x2019;s disease (Crohn&#x2019;s Disease Activity Index (CDAI) </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">220 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">400) in a randomised, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">double-blinded, placebo-controlled, dose-response study. Of these 108 patients, 27 were treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the recommended dosage of infliximab 5 mg/kg. All patients had experienced an inadequate response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to prior conventional therapies. Concurrent use of stable doses of conventional therapies was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">permitted, and 92% of patients continued to receive these therapies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The primary endpoint was the proportion of patients who experienced a clinical response, defined as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">decrease in CDAI by </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">70 points from baseline at the 4-week evaluation and without an increase in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">use of medicinal products or surgery for Crohn&#x2019;s disease. Patients who responded at week 4 were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">followed to week 12. Secondary endpoints included the proportion of patients in clinical remission at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 4 (CDAI &lt;150) and clinical response over time. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At week 4, following administration of a single dose, 22/27 (81%) of infliximab-treated patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receiving a 5 mg/kg dose achieved a clinical response vs. 4/25 (16%) of the placebo-treated patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p &lt;0.001). Also at week 4, 13/27 (48%) of infliximab-treated patients achieved a clinical remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(CDAI &lt;150) vs. 1/25 (4%) of placebo-treated patients. A response was observed within 2 weeks, with </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">27 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a maximum response at 4 weeks. At the last observation at 12 weeks, 13/27 (48%) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab-treated patients were still responding. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Maintenance treatment in moderately to severely active Crohn&#x2019;s disease in adults </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of repeated infusions with infliximab was studied in a 1-year clinical study (ACCENT I). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A total of 573 patients with moderately to severely active Crohn&#x2019;s disease (CDAI </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">220 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">400) received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a single infusion of 5 mg/kg at week 0. 178 of the 580 enrolled patients (30.7%) were defined as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">having severe disease (CDAI score &gt; 300 and concomitant corticosteroid and/or immunosuppressants) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">corresponding to the population defined in the indication (see section 4.1). At week 2, all patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">assessed for clinical response and randomised to one of 3 treatment groups; a placebo maintenance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group, 5 mg/kg maintenance group and 10 mg/kg maintenance group. All 3 groups received repeated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusions at week 2, 6 and every 8 weeks thereafter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Of the 573 patients randomised, 335 (58%) achieved clinical response by week 2. These patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">classified as week-2 responders and were included in the primary analysis (see Table 5). Among </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients classified as non-responders at week 2, 32% (26/81) in the placebo maintenance group and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">42% (68/163) in the infliximab group achieved clinical response by week 6. There was no difference </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">between groups in the number of late responders thereafter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The co-primary endpoints were the proportion of patients in clinical remission (CDAI &lt;150) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 30 and time to loss of response through week 54. Corticosteroid tapering was permitted after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 6. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:102pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on response and remission rate, data from ACCENT I (Week-2 responders)</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:304pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACCENT I (Week-2 responders) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:347pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">% of Patients</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(n=110) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:335pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:330pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:341pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(n=113) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:439pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:446pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(n=112) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Median time to loss of response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">through week 54 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">19 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:338pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">38 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.002) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&gt;54 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 30 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:235pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:311pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:416pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical Response</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">27.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">51.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">59.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical Remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">20.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">38.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.003) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">45.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Steroid-Free Remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10.7 (6/56) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:331pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">31.0 (18/58) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.008) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:440pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">36.8 (21/57) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 54 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:235pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:358pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:467pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical Response</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">15.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">38.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">47.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical Remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">13.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">28.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.007) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">38.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sustained Steroid-Free </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remission</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5.7 (3/53) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:331pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">17.9 (10/56) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.075) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:440pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">28.6 (16/56) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.002) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reduction in CDAI </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">25% and </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">70 points. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">b  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CDAI &lt;150 at both Week 30 and 54 and not receiving corticosteroids in the 3 months prior to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 54 among patients who were receiving corticosteroids at baseline.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Beginning at week 14, patients who had responded to treatment, but subsequently lost their clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">benefit, were allowed to cross over to a dose of infliximab 5 mg/kg higher than the dose to which they </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were originally randomised. Eighty nine percent (50/56) of patients who lost clinical response on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab 5 mg/kg maintenance therapy after week 14 responded to treatment with infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 mg/kg. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">28 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Improvements in quality of life measures, a reduction in disease-related hospitalisations and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">corticosteroid use were seen in the infliximab maintenance groups compared with the placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintenance group at weeks 30 and 54. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab with or without AZA was assessed in a randomised, double-blind, active comparator study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(SONIC) of 508 adult patients with moderate to severe Crohn&#x2019;s disease (CDAI </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">220 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">450) who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">naive to biologics and immunosuppressants and had a median disease duration of 2.3 years. At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline 27.4% of patients were receiving systemic corticosteroids, 14.2% of patients were receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">budesonide, and 54.3% of patients were receiving 5-ASA compounds. Patients were randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receive AZA monotherapy, infliximab monotherapy, or infliximab plus AZA combination therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab was administered at a dose of 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks. AZA was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">given at a dose of 2.5 mg/kg daily. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The primary endpoint of the study was corticosteroid-free clinical remission at week 26, defined as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients in clinical remission (CDAI of &lt;150) who, for at least 3 weeks, had not taken oral systemic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">corticosteroids (prednisone or equivalent) or budesonide at a dose &gt;6 mg/day. For results see Table 6. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The proportions of patients with mucosal healing at week 26 were significantly greater in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab plus AZA combination (43.9%, p&lt;0.001) and infliximab monotherapy groups (30.1%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">p=0.023) compared to the AZA monotherapy group (16.5%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:95pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Percent of patients achieving corticosteroid-free clinical remission at Week 26, SONIC</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:150pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:256pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">AZA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:238pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:335pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:329pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:427pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab + AZA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:421pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Combination therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 26 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:235pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:311pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:416pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">All randomised patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:253pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">30.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:249pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(51/170) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">44.4% (75/169) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:334pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p=0.006)* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:433pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">56.8% (96/169) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:443pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p&lt;0.001)* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">* p-values represent each infliximab treatment group vs. AZA monotherapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Similar trends in the achievement of corticosteroid-free clinical remission were observed at week 50. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Furthermore, improved quality of life as measured by IBDQ was observed with infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Induction treatment in fistulising active Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy was assessed in a randomised, double-blinded, placebo-controlled study in 94 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with fistulising Crohn&#x2019;s disease who had fistulae that were of at least 3 months&#x2019; duration. Thirty one of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">these patients were treated with infliximab 5 mg/kg. Approximately 93% of the patients had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">previously received antibiotic or immunosuppressive therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Concurrent use of stable doses of conventional therapies was permitted, and 83% of patients continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to receive at least one of these therapies. Patients received three doses of either placebo or infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">at weeks 0, 2 and 6. Patients were followed up to 26 weeks. The primary endpoint was the proportion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of patients who experienced a clinical response, defined as </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50% reduction from baseline in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">number of fistulae draining upon gentle compression on at least two consecutive visits (4 weeks apart), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">without an increase in the use of medicinal products or surgery for Crohn&#x2019;s disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sixty eight percent (21/31) of infliximab-treated patients receiving a 5 mg/kg dose regimen achieved a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical response vs. 26% (8/31) placebo-treated patients (p=0.002). The median time to onset of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response in the infliximab-treated group was 2 weeks. The median duration of response was 12 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Additionally, closure of all fistulae was achieved in 55% of infliximab-treated patients compared with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">13% of placebo-treated patients (p=0.001). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Maintenance treatment in fistulising active Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of repeated infusions with infliximab in patients with fistulising Crohn&#x2019;s disease was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studied in a 1-year clinical study (ACCENT II). A total of 306 patients received 3 doses of infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg at week 0, 2 and 6. At baseline, 87% of the patients had perianal fistulae, 14% had abdominal </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">29 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fistulae, 9% had rectovaginal fistulae. The median CDAI score was 180. At week 14, 282 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were assessed for clinical response and randomised to receive either placebo or 5 mg/kg infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">every 8 weeks through week 46. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week-14 responders (195/282) were analysed for the primary endpoint, which was time from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">randomisation to loss of response (see Table 7). Corticosteroid tapering was permitted after week 6. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:132pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on response rate, data from ACCENT II (Week-14 responders)</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:153pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:302pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACCENT II (Week-14 responders) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:153pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:266pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:255pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(n=99) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:356pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:351pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:358pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(5 mg/kg) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(n=96) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:459pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">p-value </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Median time to loss of response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">through week 54 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:262pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">14 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:356pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&gt;40 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;0.001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 54 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:283pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:476pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fistula Response (%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:273pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">23.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:370pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">46.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:463pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Complete fistula response (%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:273pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">19.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:370pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">36.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:463pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.009 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50% reduction from baseline in the number of draining fistulas over a period of </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">b </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Absence of any draining fistulas. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Beginning at week 22, patients who initially responded to treatment and subsequently lost their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response were eligible to cross over to active re-treatment every 8 weeks at a dose of infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg higher than the dose to which they were originally randomised. Among patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab 5 mg/kg group who crossed over because of loss of fistula response after week 22, 57% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(12/21) responded to re-treatment with infliximab 10 mg/kg every 8 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was no significant difference between placebo and infliximab for the proportion of patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sustained closure of all fistulas through week 54, for symptoms such as proctalgia, abscesses and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">urinary tract infection or for number of newly developed fistulas during treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance therapy with infliximab every 8 weeks significantly reduced disease-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hospitalisations and surgeries compared with placebo. Furthermore, a reduction in corticosteroid use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and improvements in quality of life were observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adult ulcerative colitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of infliximab were assessed in two (ACT 1 and ACT 2) randomised, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">double-blind, placebo-controlled clinical studies in adult patients with moderately to severely active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ulcerative colitis (Mayo score 6 to 12; Endoscopy subscore </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2) with an inadequate response to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">conventional therapies [oral corticosteroids, aminosalicylates and/or immunomodulators (6-MP, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">AZA)]. Concomitant stable doses of oral aminosalicylates, corticosteroids, and/or immunomodulatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">agents were permitted. In both studies, patients were randomised to receive either placebo, 5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab, or 10 mg/kg infliximab at weeks 0, 2, 6, 14 and 22, and in ACT 1 at weeks 30, 38 and 46. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Corticosteroid taper was permitted after week 8. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">30 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:95pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on clinical response, clinical remission and mucosal healing at Weeks 8 and 30. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:221pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Combined data from ACT 1 &amp; 2</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:250pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:320pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:389pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:463pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Combined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Subjects randomised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:260pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">244 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:330pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">242 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">242 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:477pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">484 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Percentage of subjects in clinical response and in sustained clinical response</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical response at Week 8</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:254pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">33.2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">66.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">65.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">66.1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical response at Week 30</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:254pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">27.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">49.6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">55.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">52.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sustained response (clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response at both Week 8 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 30)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:254pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">19.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">45.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:410pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">49.6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:486pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">47.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Percentage of subjects in clinical remission and sustained remission</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical remission at Week 8</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:254pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10.2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">36.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">29.8% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">33.1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical remission at Week 30</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:254pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">13.1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">29.8% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">36.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">33.1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sustained remission(in remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">at both Week 8 and Week 30)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:256pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">19.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:410pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">24.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:486pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">21.7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Percentage of subjects with mucosal healing</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mucosal healing at Week 8</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:254pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">32.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">61.2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">60.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">60.7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mucosal healing at Week 30</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:254pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">27.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">48.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">52.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50.6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">p &lt;0.001, for each infliximab treatment group vs. placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of infliximab through week 54 was assessed in the ACT 1 study. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At 54 weeks, 44.9% of patients in the combined infliximab treatment group were in clinical response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to 19.8% in the placebo treatment group (p&lt;0.001). Clinical remission and mucosal healing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occurred in a greater proportion of patients in the combined infliximab treatment group compared to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the placebo treatment group at week 54 (34.6% vs. 16.5%, p&lt;0.001 and 46.1% vs. 18.2%, p&lt;0.001, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">respectively). The proportions of patients in sustained response and sustained remission at week 54 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were greater in the combined infliximab treatment group than in the placebo treatment group (37.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vs. 14.0%, p&lt;0.001; and 20.2% vs. 6.6%, p&lt;0.001, respectively). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A greater proportion of patients in the combined infliximab treatment group were able to discontinue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">corticosteroids while remaining in clinical remission compared to the placebo treatment group at both </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 30 (22.3% vs. 7.2%, p &lt;0.001, pooled ACT 1 &amp; ACT 2 data) and week 54 (21.0% vs. 8.9%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">p=0.022, ACT 1 data). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The pooled data analysis from the ACT 1 and ACT 2 studies and their extensions, analysed from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline through 54 weeks, demonstrated a reduction of ulcerative colitis-related hospitalisations and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">surgical procedures with infliximab treatment. The number of ulcerative colitis-related hospitalisations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was significantly lower in the 5 and 10 mg/kg infliximab treatment groups than in the placebo group </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(mean number of hospitalisations per 100 subject-years: 21 and 19 vs. 40 in the placebo group; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">p=0.019 and p=0.007, respectively). The number of ulcerative colitis-related surgical procedures was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">also lower in the 5 and 10 mg/kg infliximab treatment groups than in the placebo group (mean number </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of surgical procedures per 100 subject-years: 22 and 19 vs. 34</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">; </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">p=0.145 and p=0.022, respectively). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The proportion of subjects who underwent colectomy at any time within 54 weeks following the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion of study agent were collected and pooled from the ACT 1 and ACT 2 studies and their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">extensions. Fewer subjects underwent colectomy in the 5 mg/kg infliximab group (28/242 or 11.6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[N.S.]) and the 10 mg/kg infliximab group (18/242 or 7.4% [p=0.011]) than in the placebo group </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(36/244; 14.8%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The reduction in incidence of colectomy was also examined in another randomised, double-blind study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(C0168Y06) in hospitalised patients (n=45) with moderately to severely active ulcerative colitis who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">failed to respond to intravenous corticosteroids and who were therefore at higher risk for colectomy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Significantly fewer colectomies occurred within 3 months of study infusion in patients who received a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">single dose of 5 mg/kg infliximab compared to patients who received placebo (29.2% vs. 66.7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">respectively, p=0.017). </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">31 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In ACT 1 and ACT 2, infliximab improved quality of life, confirmed by statistically significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">improvement in both a disease specific measure, IBDQ, and by improvement in the generic 36-item </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">short form survey SF-36. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adult ankylosing spondylitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Efficacy and safety of infliximab were assessed in two multicentre, double-blind, placebo-controlled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies in patients with active ankylosing spondylitis (Bath Ankylosing Spondylitis Disease Activity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Index [BASDAI] score </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 4 and spinal pain </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 4 on a scale of 1-10). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the first study (P01522), which had a 3 month double-blind phase, 70 patients received either </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg infliximab or placebo at weeks 0, 2, 6 (35 patients in each group). At week 12, placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients were switched to infliximab 5 mg/kg every 6 weeks up to week 54. After the first year of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">study, 53 patients continued into an open-label extension to week 102. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the second clinical study (ASSERT), 279 patients were randomised to receive either placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Group 1, n=78) or 5 mg/kg infliximab (Group 2, n=201) at 0, 2 and 6 weeks and every 6 weeks to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 24. Thereafter, all subjects continued on infliximab every 6 weeks to week 96. Group 1 received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg infliximab. In Group 2, starting with the week 36 infusion, patients who had a BASDAI </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 consecutive visits, received 7.5 mg/kg infliximab every 6 weeks thereafter through week 96. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In ASSERT, improvement in signs and symptoms was observed as early as week 2. At week 24, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">number of ASAS 20 responders was 15/78 (19%) in the placebo group, and 123/201 (61%) in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg infliximab group (p&lt;0.001). There were 95 subjects from group 2 who continued on 5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">every 6 weeks. At 102 weeks there were 80 subjects still on infliximab treatment and among those, 71 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(89%) were ASAS 20 responders. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In P01522, improvement in signs and symptoms was also observed as early as week 2. At week 12, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the number of BASDAI 50 responders were 3/35 (9%) in the placebo group, and 20/35 (57%) in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg group (p&lt;0.01). There were 53 subjects who continued on 5 mg/kg every 6 weeks. At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">102 weeks there were 49 subjects still on infliximab treatment and among those, 30 (61%) were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">BASDAI 50 responders. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In both studies, physical function and quality of life as measured by the BASFI and the physical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">component score of the SF-36 were also improved significantly. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adult psoriatic arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Efficacy and safety were assessed in two multicentre, double-blind, placebo-controlled studies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with active psoriatic arthritis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the first clinical study (IMPACT), efficacy and safety of infliximab were studied in 104 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with active polyarticular psoriatic arthritis. During the 16-week double-blind phase, patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">either 5 mg/kg infliximab or placebo at weeks 0, 2, 6, and 14 (52 patients in each group). Starting at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 16, placebo patients were switched to infliximab and all patients subsequently received 5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab every 8 weeks up to week 46. After the first year of the study, 78 patients continued into an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">open-label extension to week 98. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the second clinical study (IMPACT 2), efficacy and safety of infliximab were studied in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">200 patients with active psoriatic arthritis (</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 swollen joints and </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 tender joints). Forty six percent of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients continued on stable doses of methotrexate (</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">25 mg/week). During the 24-week double-blind </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">phase, patients received either 5 mg/kg infliximab or placebo at weeks 0, 2, 6, 14, and 22 (100 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in each group). At week 16, 47 placebo patients with &lt;10% improvement from baseline in both </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">swollen and tender joint counts were switched to infliximab induction (early escape). At week 24, all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo-treated patients crossed over to infliximab induction. Dosing continued for all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">through week 46. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">32 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Key efficacy results for IMPACT and IMPACT 2 are shown in Table 9 below: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:169pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ACR and PASI in IMPACT and IMPACT 2</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:219pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">IMPACT </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:401pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">IMPACT 2* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:160pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:154pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Week 16) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Week 16) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:280pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:280pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Week 98) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:343pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Week 24) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:405pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:405pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Week 24) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Week 54) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">randomised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:171pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:234pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N/A</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:358pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:420pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:484pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACR response  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:177pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:177pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:171pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:240pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:240pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:234pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:303pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:303pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:298pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">78 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:366pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:366pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:358pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:429pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:429pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:420pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:492pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:492pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:484pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACR 20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:159pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 (10%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:219pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">34 (65%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:283pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">48 (62%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:345pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">16 (16%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:408pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">54 (54%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">53 (53%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACR 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:162pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0 (0%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:219pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">24 (46%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:283pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">35 (45%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:351pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4 (4%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:408pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">41 (41%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">33 (33%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACR 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:162pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0 (0%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:219pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">15 (29%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:283pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">27 (35%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:351pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 (2%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:408pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">27 (27%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">20 (20%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PASI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:177pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:240pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:303pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:366pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:366pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:360pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">87 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:429pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:429pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:423pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">83 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:492pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:492pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:487pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">82 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response** </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:177pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:240pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:303pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:351pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 (1%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:408pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50 (60%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:467pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">40 (48.8%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ITT-analysis where subjects with missing data were included as non-responders. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 98 data for IMPACT includes combined placebo crossover and infliximab patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">entered the open-label extension. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">b</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on patients with PASI &gt;2.5 at baseline for IMPACT, and patients with &gt;3% BSA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">psoriasis skin involvement at baseline in IMPACT 2. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">** PASI 75 response for IMPACT not included due to low N; p&lt;0.001 for infliximab vs. placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">at week 24 for IMPACT 2. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In IMPACT and IMPACT 2, clinical responses were observed as early as week 2 and were maintained </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">through week 98 and week 54, respectively. Efficacy has been demonstrated with or without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant use of methotrexate. Decreases in parameters of peripheral activity characteristic of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">psoriatic arthritis (such as number of swollen joints, number of painful/tender joints, dactylitis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">presence of enthesopathy) were seen in the infliximab-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Radiographic changes were assessed in IMPACT 2. Radiographs of hands and feet were collected at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline, weeks 24 and 54. Infliximab treatment reduced the rate of progression of peripheral joint </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">damage compared with placebo treatment at the week 24 primary endpoint as measured by change </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">from baseline in total modified vdH-S score (mean &#xb1; SD score was 0.82 &#xb1; 2.62 in the placebo group </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared with -0.70 &#xb1; 2.53 in the infliximab group; p&lt;0.001). In the infliximab group, the mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">change in total modified vdH-S score remained below 0 at the week 54 timepoint. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab-treated patients demonstrated significant improvement in physical function as assessed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HAQ. Significant improvements in health-related quality of life were also demonstrated as measured </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">by the physical and mental component summary scores of the SF-36 in IMPACT 2. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adult psoriasis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of infliximab was assessed in two multicentre, randomised, double-blind studies: SPIRIT </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and EXPRESS. Patients in both studies had plaque psoriasis (Body Surface Area [BSA] </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10% and </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">33 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Psoriasis Area and Severity Index [PASI] score </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">12). The primary endpoint in both studies was the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">percent of patients who achieved </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">75% improvement in PASI from baseline at week 10. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">SPIRIT evaluated the efficacy of infliximab induction therapy in 249 patients with plaque psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that had previously received PUVA or systemic therapy. Patients received either 3 or 5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab or placebo infusions at weeks 0, 2 and 6. Patients with a PGA score </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 were eligible to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receive an additional infusion of the same treatment at week 26. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In SPIRIT, the proportion of patients achieving PASI 75 at week 10 was 71.7% in the 3 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab group, 87.9% in the 5 mg/kg infliximab group, and 5.9% in the placebo group (p&lt;0.001). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">By week 26, twenty weeks after the last induction dose, 30% of patients in the 5 mg/kg group and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">13.8% of patients in the 3 mg/kg group were PASI 75 responders. Between weeks 6 and 26, symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of psoriasis gradually returned with a median time to disease relapse of &gt;20 weeks. No rebound was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EXPRESS evaluated the efficacy of infliximab induction and maintenance therapy in 378 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with plaque psoriasis. Patients received 5 mg/kg infliximab- or placebo-infusions at weeks 0, 2 and 6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">followed by maintenance therapy every 8 weeks through week 22 in the placebo group and through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 46 in the infliximab group. At week 24, the placebo group crossed over to infliximab induction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapy (5 mg/kg) followed by infliximab maintenance therapy (5 mg/kg). Nail psoriasis was assessed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">using the Nail Psoriasis Severity Index (NAPSI). Prior therapy with PUVA, methotrexate, ciclosporin, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or acitretin had been received by 71.4% of patients, although they were not necessarily therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">resistant. Key results are presented in Table 10. In infliximab treated subjects, significant PASI 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">responses were apparent at the first visit (week 2) and PASI 75 responses by the second visit (week 6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Efficacy was similar in the subgroup of patients that were exposed to previous systemic therapies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to the overall study population. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:277pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 10 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:85pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Summary of PASI response, PGA response and percent of patients with all nails cleared at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:222pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Weeks 10, 24 and 50. EXPRESS</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:276pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo &#x2192; Infliximab</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:306pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:297pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(at week 24) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:434pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:439pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 10 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:324pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:457pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:319pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">77 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">301 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;90% improvement</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 (1.3%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:428pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">172 (57.1%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;75% improvement </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 (2.6%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:428pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">242 (80.4%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;50% improvement</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 (7.8%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">274 (91.0%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PGA of cleared (0) or minimal (1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 (3.9%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:426pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">242 (82.9%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> ab</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PGA of cleared (0), minimal (1), or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mild (2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">14 (18.2%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:426pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">275 (94.2%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> ab</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 24 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:324pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:457pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:319pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">77 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">276 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;90% improvement</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 (1.3%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:428pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">161 (58.3%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;75% improvement </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 (3.9%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:428pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">227 (82.2%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;50% </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 (6.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">248 (89.9%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PGA of cleared (0) or minimal (1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 (2.6%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:428pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">203 (73.6%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PGA of cleared (0), minimal (1), or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mild (2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">15 (19.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:428pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">246 (89.1%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 50 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:324pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:457pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:319pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">68 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">281 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;90% improvement</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">34 (50.0%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">127 (45.2%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;75% improvement </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">52 (76.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">170 (60.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;50% improvement</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">61 (89.7%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">193 (68.7%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PGA of cleared (0) or minimal (1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">46 (67.6%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">149 (53.0%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PGA of cleared (0), minimal (1), or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mild (2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">59 (86.8%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">189 (67.3%) </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">34 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:276pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo &#x2192; Infliximab</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:306pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:297pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(at week 24) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:434pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:439pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">All nails cleared</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.96pt">c</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:457pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 10 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/65(1.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:426pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">16/235 (6.8%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 24 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:298pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3/65 (4.6%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:420pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">58/223 (26.0%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:293pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">27/64 (42.2%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:423pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">92/226 (40.7%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">p &lt;0.001, for each infliximab treatment group vs. control. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">b </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">n = 292. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">c </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Analysis was based on subjects with nail psoriasis at baseline (81.8% of subjects). Mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline NAPSI scores were 4.6 and 4.3 in infliximab and placebo group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Significant improvements from baseline were demonstrated in DLQI (p&lt;0.001) and the physical and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mental component scores of the SF 36 (p&lt;0.001 for each component comparison).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric Crohn&#x2019;s disease (6 to 17 years) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the REACH study, 112 patients (6 to 17 years, median age 13.0 years) with moderate to severe, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">active Crohn&#x2019;s disease (median paediatric CDAI of 40) and an inadequate response to conventional </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapies were to receive 5 mg/kg infliximab at weeks 0, 2, and 6. All patients were required to be on a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">stable dose of 6-MP, AZA or MTX (35% were also receiving corticosteroids at baseline). Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">assessed by the investigator to be in clinical response at week 10 were randomised and received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg infliximab at either q8 weeks or q12 weeks as a maintenance treatment regimen. If response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was lost during maintenance treatment, crossing over to a higher dose (10 mg/kg) and/or shorter </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dosing interval (q8 weeks) was allowed. Thirty two (32) evaluable paediatric patients crossed over </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(9 subjects in the q8 weeks and 23 subjects in the q12 weeks maintenance groups). Twenty four of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">these patients (75.0%) regained clinical response after crossing over. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The proportion of subjects in clinical response at week 10 was 88.4% (99/112). The proportion of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subjects achieving clinical remission at week 10 was 58.9% (66/112). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At week 30, the proportion of subjects in clinical remission was higher in the q8 week (59.6%, 31/52) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">than the q12 week maintenance treatment group (35.3%, 18/51; p=0.013). At week 54, the figures </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were 55.8% (29/52) and 23.5% (12/51) in the q8 weeks and q12 weeks maintenance groups, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">respectively (p &lt; 0.001). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Data about fistulas were derived from PCDAI scores. Of the 22 subjects that had fistulas at baseline, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">63.6% (14/22), 59.1% (13/22) and 68.2% (15/22) were in complete fistula response at week 10, 30 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">54, respectively, in the combined q8 weeks and q12 weeks maintenance groups. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In addition, statistically and clinically significant improvements in quality of life and height, as well as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a significant reduction in corticosteroid use, were observed versus baseline. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric ulcerative colitis (6 to 17</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">years) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of infliximab were assessed in a multicentre, randomised, open-label, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">parallel-group clinical study (C0168T72) in 60 paediatric patients aged 6 through 17 years (median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">age 14.5 years) with moderately to severely active ulcerative colitis (Mayo score of 6 to 12; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">endoscopic subscore &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 2) with an inadequate response to conventional therapies. At baseline 53% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients were receiving immunomodulator therapy (6-MP, AZA and/or MTX) and 62% of patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were receiving corticosteroids. Discontinuation of immunomodulators and corticosteroid taper were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">permitted after week 0. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">All patients received an induction regimen of 5 mg/kg infliximab at weeks 0, 2, and 6. Patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">did not respond to infliximab at week 8 (n=15) received no further medicinal product and returned for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">safety follow-up. At week 8, 45 patients were randomised and received 5</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mg/kg infliximab at either </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q8</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weeks or q12</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weeks as a maintenance treatment regimen. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">35 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:54pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The proportion of patients in clinical response at week 8 was 73.3% (44/60). Clinical response at week</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">8 was similar between those with or without concomitant immunomodulator use at baseline. Clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">remission at week 8 was 33.3% (17/51) as measured by the Paediatric Ulcerative Colitis Activity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Index (PUCAI) score. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At week 54, the proportion of patients in clinical remission as measured by the PUCAI score was 38% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(8/21) in the q8</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week maintenance group and 18% (4/22) in the q12</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week maintenance treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group. For patients receiving corticosteroids at baseline, the proportion of patients in remission and not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receiving corticosteroids at week 54 was 38.5% (5/13) for the q8</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week and 0% (0/13) for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q12</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week maintenance treatment group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In this study, there were more patients in the 12 to 17</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">year age group than in the 6 to 11</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">year age </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group (45/60 vs.15/60). While the numbers of patients in each subgroup are too small to draw </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">definitive conclusions about the effect of age, there was a higher number of patients in the younger age </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group who stepped up in dose or discontinued treatment due to inadequate efficacy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Other paediatric indications </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The European Medicines Agency has waived the obligation to submit the results of studies with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reference medicinal product containing infliximab in all subsets of the paediatric population in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and Crohn&apos;s disease (see section 4.2 for information on paediatric use). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacokinetic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Single intravenous infusions of 1, 3, 5, 10 or 20 mg/kg of infliximab yielded dose proportional </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increases in the maximum serum concentration (C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) and area under the concentration-time curve </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(AUC). The volume of distribution at steady state (median V</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of 3.0 to 4.1 litres) was not dependent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">on the administered dose and indicated that infliximab is predominantly distributed within the vascular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compartment. No time-dependency of the Pharmacokinetics was observed. The elimination pathways </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">for infliximab have not been characterised. Unchanged infliximab was not detected in urine. No major </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">age- or weight-related differences in clearance or volume of distribution were observed in rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthritis patients. The pharmacokinetics of infliximab in elderly patients has not been studied. Studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have not been performed in patients with liver or renal disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At single doses of 3, 5, or 10 mg/kg, the median C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values were 77, 118 and 277 micrograms/mL, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">respectively. The median terminal half-life at these doses ranged from 8 to 9.5 days. In most patients, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab could be detected in the serum for at least 8 weeks after the recommended single dose of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg for Crohn&#x2019;s disease and the rheumatoid arthritis maintenance dose of 3 mg/kg every 8 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Repeated administration of infliximab (5 mg/kg at 0, 2 and 6 weeks in fistulising Crohn&#x2019;s disease, 3 or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 mg/kg every 4 or 8 weeks in rheumatoid arthritis) resulted in a slight accumulation of infliximab in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serum after the second dose. No further clinically relevant accumulation was observed. In most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fistulising Crohn&#x2019;s disease patients, infliximab was detected in serum for 12 weeks (range 4-28 weeks) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">after administration of the regimen. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Population pharmacokinetic analysis based on data obtained from patients with ulcerative colitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(N=60), Crohn&#x2019;s disease (N=112), juvenile rheumatoid arthritis (N=117) and Kawasaki disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(N=16) with an overall age range from 2 months to 17 years indicated that exposure to infliximab was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dependent on body weight in a non-linear way. Following administration of 5 mg/kg infliximab every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">8 weeks, the predicted median steady-state infliximab exposure (area under concentration-time curve </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">at steady state, AUCss) in paediatric patients aged 6 years to 17 years was approximately 20% lower </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">than the predicted median steady-state medicinal product exposure in adults. The median AUCss in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">paediatric patients aged 2 years to less than 6 years was predicted to be approximately 40% lower than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:769pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that in adults, although the number of patients supporting this estimate is limited. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">36 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab does not cross react with TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> from species other than human and chimpanzees. Therefore, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">conventional preclinical safety data with infliximab are limited. In a developmental toxicity study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">conducted in mice using an analogous antibody that selectively inhibits the functional activity of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mouse TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, there was no indication of maternal toxicity, embryotoxicity or teratogenicity. In a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fertility and general reproductive function study, the number of pregnant mice was reduced following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration of the same analogous antibody. It is not known whether this finding was due to effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">on the males and/or the females. In a 6-month repeated dose toxicity study in mice, using the same </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">analogous antibody against mouse TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, crystalline deposits were observed on the lens capsule of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">some of the treated male mice. No specific ophthalmologic examinations have been performed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients to investigate the relevance of this finding for humans. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Long-term studies have not been performed to evaluate the carcinogenic potential of infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies in mice deficient in TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> demonstrated no increase in tumours when challenged with known </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tumour initiators and/or promoters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sucrose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Polysorbate 80 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sodium dihydrogen phosphate monohydrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Disodium phosphate dihydrate  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Incompatibilities </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shelf life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Before reconstitution: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 years at 2&#xb0;C &#x2013; 8&#xb0;C. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima may be stored at temperatures up to a maximum of 25&#xb0;C for a single period of up to 6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">months, but not exceeding the original expiry date. The new expiry date must be written on the carton. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Upon removal from refrigerated storage, Remsima must not be returned to refrigerated storage. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After reconstitution and dilution: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Chemical and physical in use stability of the diluted solution has been demonstrated for up to 60 days </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">at 2 &#xb0;C to 8 &#xb0;C and for an additional 24 hours at 25</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#xb0;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C after removal from refrigeration. From a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">microbiological point of view, the infusion solution should be administered immediately, in use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">storage times and conditions prior to use are the responsibility of the user and would normally not be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">longer than 24 hours at 2&#xb0;C &#x2013; 8&#xb0;C, unless reconstitution/dilution has been taken place in controlled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and validated aseptic conditions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Store in a refrigerator (2&#xb0;C &#x2013; 8&#xb0;C). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For storage conditions up to 25&#xb0;C before reconstitution of the medicinal product, see section 6.3. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">37 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For storage conditions after reconstitution of the medicinal product, see section 6.3</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt">.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nature and contents of container </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Type 1 glass vial with a (butyl) rubber stopper and an aluminium seal with a flip-off button. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pack sizes of 1, 2, 3, 4, 5 vials. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not all pack sizes may be marketed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for disposal and other handling </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The dose and the number of Remsima vials have to be calculated. Each Remsima vial contains </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 mg infliximab. The required total volume of reconstituted Remsima solution has to be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">calculated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Under aseptic conditions, each Remsima vial should be reconstituted with 10 mL of water for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">injections, using a syringe equipped with a 21-gauge (0.8 mm) or smaller needle. The flip-top </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">from the vial has to be removed and the top has to be wiped with a 70% alcohol swab. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">syringe needle should be inserted into the vial through the centre of the rubber stopper and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">stream of water for injections directed to the glass wall of the vial. The solution has to be gently </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">swirled by rotating the vial to dissolve the powder. Prolonged or vigorous agitation must be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">avoided. THE VIAL MUST NOT BE SHAKEN. Foaming of the solution on reconstitution may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occur. The reconstituted solution should stand for 5 minutes. The solution should be colourless </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to light yellow and opalescent. The solution may develop a few fine translucent particles, as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab is a protein. The solution must not be used if opaque particles, discolouration, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">other foreign particles are present. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The required volume of the reconstituted Remsima solution should be diluted to 250 mL with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sodium chloride 9 mg/mL (0.9%) solution for infusion. Do not dilute the reconstituted Remsima </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">solution with any other diluent. The dilution can be accomplished by withdrawing a volume of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the sodium chloride 9 mg/mL (0.9%) solution for infusion from the 250-mL glass bottle or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion bag equal to the volume of reconstituted Remsima. The required volume of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reconstituted Remsima solution should slowly be added to the 250-mL infusion bottle or bag </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and gently be mixed. For volumes greater than 250 ml, either use a larger infusion bag (e.g. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">500 ml, 1000 ml) or use multiple 250 ml infusion bags to ensure that the concentration of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion solution does not exceed 4 mg/ml. If stored refrigerated after reconstitution and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dilution, the infusion solution must be allowed to equilibrate at room temperature to 25 &#xb0;C for 3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hours prior to Step 4 (infusion). Storage beyond 24 hours at 2 &#xb0;C - 8 &#xb0;C applies to preparation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima in the infusion bag only. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The infusion solution has to be administered over a period of not less than the infusion time </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended (see section 4.2). Only an infusion set with an in-line, sterile, non-pyrogenic, low </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">protein-binding filter (pore size 1.2 micrometre or less) should be used. Since no preservative is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">present, it is recommended that the administration of the solution for infusion is to be started as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">soon as possible and within 3 hours of reconstitution and dilution. If not used immediately, in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">use storage times and conditions prior to use are the responsibility of the user and would </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">normally not be longer than 24 hours at 2&#xb0;C to 8&#xb0;C, unless reconstitution/dilution has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">taken place in controlled and validated aseptic conditions (see section 6.3 above). Any unused </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">portion of the infusion solution should not be stored for reuse. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima should be visually inspected for particulate matter or discolouration prior to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration. If visibly opaque particles, discolouration or foreign particles are observed it </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should not be used. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">38 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">requirements. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Celltrion Healthcare Hungary Kft.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1062 Budapest </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">V&#xe1;ci &#xfa;t 1-3. WestEnd Office Building B torony </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hungary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">8. MARKETING AUTHORISATION NUMBER(S)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/002 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/003 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/004 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/005 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of first authorisation: 10 September 2013 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of latest renewal: 21 June 2018 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10. DATE OF REVISION OF THE TEXT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:371pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">39 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 120 mg solution for injection in pre-filled syringe </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 120 mg solution for injection in pre-filled pen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 120 mg solution for injection in pre-filled syringe </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each 1 mL single dose pre-filled syringe contains 120 mg of infliximab*. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 120 mg solution for injection in pre-filled pen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each 1 mL single dose pre-filled pen contains 120 mg of infliximab*.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">* Infliximab is a chimeric human-murine IgG1 monoclonal antibody produced in murine hybridoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cells by recombinant DNA technology.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipient(s) with known effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sorbitol 45 mg per 1 mL  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Solution for injection (injection). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clear to opalescent, colourless to pale brown solution.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">CLINICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">THERAPEUTIC INDICATIONS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima, in combination with methotrexate, is indicated for the reduction of signs and symptoms as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">well as the improvement in physical function in:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adult patients with active disease when the response to disease-modifying antirheumatic drugs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(DMARDs), including methotrexate, has been inadequate.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adult patients with severe, active and progressive disease not previously treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">methotrexate or other DMARDs.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In these patient populations, a reduction in the rate of the progression of joint damage, as measured by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">X-ray, has been demonstrated (see section 5.1).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Crohn&#x2019;s disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is indicated for: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment of moderately to severely active Crohn&#x2019;s disease, in adult patients who have not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">responded despite a full and adequate course of therapy with a corticosteroid and/or an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunosuppressant; or who are intolerant to or have medical contraindications for such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment of fistulising, active Crohn&#x2019;s disease, in adult patients who have not responded despite </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a full and adequate course of therapy with conventional treatment (including antibiotics, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">drainage and immunosuppressive therapy). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">40 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ulcerative colitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is indicated for treatment of moderately to severely active ulcerative colitis in adult patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">who have had an inadequate response to conventional therapy including corticosteroids and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraindications for such therapies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ankylosing spondylitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">responded inadequately to conventional therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Psoriatic arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is indicated for treatment of active and progressive psoriatic arthritis in adult patients when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the response to previous DMARD therapy has been inadequate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima should be administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in combination with methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or alone in patients who show intolerance to methotrexate or for whom methotrexate is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraindicated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab has been shown to improve physical function in patients with psoriatic arthritis, and to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">polyarticular symmetrical subtypes of the disease (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ciclosporin, methotrexate or psoralen ultra-violet A (PUVA) (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Posology and method of administration </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima treatment is to be initiated and supervised by qualified physicians experienced in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diagnosis and treatment of conditions for which Remsima is indicated. Patients treated with Remsima </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be given the package leaflet and the patient reminder card. Instruction for use is provided in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">package leaflet.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For subsequent injections and after proper training in subcutaneous injection technique, patients may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">self-inject with Remsima if their physician determines that it is appropriate and with medical follow-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">up as necessary. Suitability of the patient for subcutaneous home use should be assessed and patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be advised to inform their healthcare professional if they experience symptoms of an allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reaction before administering the next dose. Patients should seek immediate medical attention if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">developing symptoms of serious allergic reactions (see section 4.4).</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">During Remsima treatment, other concomitant therapies, e.g., corticosteroids and immunosuppressants </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be optimised.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is important to check the product labels to ensure that the correct formulation (intravenous or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subcutaneous) is being administered to the patient, as prescribed. Remsima subcutaneous formulation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is not intended for intravenous administration and should be administered via a subcutaneous injection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">only. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">41 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Posology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adults (&#x2265;18 years)</span></i><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Rheumatoid arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Treatment with Remsima subcutaneous formulation should be initiated with loading doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab which may be intravenous or subcutaneous. When subcutaneous loading is used, Remsima </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">120 mg should be given as a subcutaneous injection followed by additional subcutaneous injections at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1, 2, 3 and 4 weeks after the first injection, then every 2 weeks thereafter. If intravenous loading doses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of infliximab are given to initiate treatment, 2 intravenous infusions of infliximab 3 mg/kg should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">given 2 weeks apart. The first treatment with Remsima administered subcutaneously should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">initiated as maintenance therapy 4 weeks after the second intravenous administration. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended maintenance dose for Remsima subcutaneous formulation is 120 mg once every 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weeks.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima must be given concomitantly with methotrexate.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Available data suggest that the clinical response is usually achieved within 12 weeks of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">benefit within the first 12 weeks of treatment (see section 5.1).</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:8.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Moderately to severely active Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weeks after the last administration of two intravenous infusions of infliximab 5 mg/kg given 2 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">apart. The recommended dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If a patient does not respond after 2 doses of intravenous infusions, no additional treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab should be given. Available data do not support further infliximab treatment, in patients not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">responding within 6 weeks of the initial infusion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fistulising, active Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 120 mg given as a subcutaneous injection 4 weeks after the last administration of two </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">intravenous infusions of infliximab 5 mg/kg given 2 weeks apart. The recommended dose for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima subcutaneous formulation is 120 mg once every 2 weeks. If a patient does not respond after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 doses (i.e. 2 intravenous infusions and 4 subcutaneous injections), no additional treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab should be given. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In Crohn&#x2019;s disease, experience with re-administration if signs and symptoms of disease recur is limited </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and comparative data on the benefit/risk of the alternative strategies for continued treatment are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lacking. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Ulcerative colitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weeks after the last administration of two intravenous infusions of infliximab 5 mg/kg given 2 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">apart. The recommended dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Available data suggest that the clinical response is usually achieved within 14 weeks of treatment, i.e. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 intravenous infusions and 4 subcutaneous injections (see section 5.1). Continued therapy should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">carefully reconsidered in patients who show no evidence of therapeutic benefit within this time period. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Ankylosing spondylitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weeks after the last administration of two intravenous infusions of infliximab 5 mg/kg given 2 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">apart. The recommended dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If a patient does not respond by 6 weeks (i.e. after 2 intravenous infusions), no additional treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with infliximab should be given. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Psoriatic arthritis </span></i></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">42 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weeks after the last administration of two intravenous infusions of infliximab 5 mg/kg given 2 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">apart. The recommended dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Psoriasis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weeks after the last administration of two intravenous infusions of infliximab 5 mg/kg given 2 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">apart. The recommended dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If a patient shows no response after 14 weeks (i.e. 2 intravenous infusions and 5 subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">injections), no additional treatment with infliximab should be given.</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Re-administration for Crohn&#x2019;s disease and rheumatoid arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">From experience with intravenous infliximab, if the signs and symptoms of disease recur, infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">can be re-administered within 16 weeks following the last administration. In clinical studies with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">intravenous infliximab, delayed hypersensitivity reactions have been uncommon and have occurred </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">after infliximab-free intervals of less than 1 year (see sections 4.4 and 4.8). The safety and efficacy of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">re-administration after an infliximab-free interval of more than 16 weeks has not been established. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">This applies to both Crohn&#x2019;s disease patients and rheumatoid arthritis patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Re-administration for ulcerative colitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">From experience with intravenous infliximab, the safety and efficacy of re-administration, other than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">every 8 weeks, has not been established (see sections 4.4 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Re-administration for ankylosing spondylitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">From experience with intravenous infliximab, the safety and efficacy of re-administration, other than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">every 6 to 8 weeks, has not been established (see sections 4.4 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Re-administration for psoriatic arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">From experience with intravenous infliximab, the safety and efficacy of re-administration, other than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">every 8 weeks, has not been established (see sections 4.4 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Re-administration for psoriasis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Limited experience from re-treatment with one single intravenous infliximab dose in psoriasis after an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">interval of 20 weeks suggests reduced efficacy and a higher incidence of mild to moderate infusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions when compared to the initial induction regimen (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Limited experience from re-treatment of intravenous infliximab following disease flare by a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">re-induction regimen suggests a higher incidence of infusion reactions, including serious ones, when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to 8-weekly maintenance treatment of intravenous infliximab (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Re-administration across indications </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In case maintenance therapy is interrupted, and there is a need to restart treatment, use of a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">re-induction regimen of intravenous infliximab is not recommended (see section 4.8). In this situation, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab should be re-initiated as a single dose of intravenous infliximab followed by the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintenance dose recommendations of subcutaneous infliximab described above given 4 weeks after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the last administration of intravenous infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Switching to and from Remsima subcutaneous formulation across indications </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">When switching from the maintenance therapy of infliximab intravenous formulation to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subcutaneous formulation of Remsima, the subcutaneous formulation may be administered 8 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">after the last administration of the intravenous infusions of infliximab.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is insufficient information regarding the switching of patients who received the intravenous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusions of infliximab higher than 3 mg/kg for rheumatoid arthritis or 5 mg/kg for Crohn&#x2019;s disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">every 8 weeks to the subcutaneous formulation of Remsima. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">43 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Information regarding switching patients from the subcutaneous formulation to the intravenous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">formulation of Remsima is not available.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Missed dose </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If patients miss an injection of Remsima subcutaneous formulation, they should be instructed to take </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the missed dose immediately in case this happens within 7 days from the missed dose, and then remain </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">on their original dosing schedule. If the dose is delayed by 8 days or more, the patients should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">instructed to skip the missed dose, wait until their next scheduled dose, and then remain on their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">original dosing schedule. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Elderly  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Specific studies of infliximab in elderly patients have not been conducted. No major age-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">differences in clearance or volume of distribution were observed in clinical studies with infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">intravenous formulations and the same is expected for subcutaneous formulation. No dose adjustment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is required (see section 5.2). For more information about the safety of infliximab in elderly patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see sections 4.4 and 4.8).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal and/or hepatic impairment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab has not been studied in these patient populations. No dose recommendations can be made </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 5.2).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of Remsima subcutaneous therapy</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#00af50"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in children aged below 18 years of age</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#008000"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not yet been established. No data are available. Therefore, subcutaneous use of Remsima is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended for use only in adults. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Method of administration  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 120 mg solution for injection in pre-filled syringe or in pre-filled pen are administered by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subcutaneous injection only. Full instructions for use are provided in the package leaflet. For the two </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">initial intravenous infusions, patients may be pre-treated with, e.g., an antihistamine, hydrocortisone </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and/or paracetamol and infusion rate may be slowed in order to decrease the risk of infusion-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions especially if infusion-related reactions have occurred previously (see section 4.4). The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">physician should ensure appropriate follow-up of patients for any systemic injection reaction and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">localised injection site reaction after the initial subcutaneous injection is administered.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity to the active substance, to other murine proteins or to any of the excipients listed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 6.1.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with tuberculosis or other severe infections such as sepsis, abscesses and opportunistic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infections (see section 4.4).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with moderate or severe heart failure (NYHA class III/IV) (see sections 4.4 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">44 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special warnings and precautions for use </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Traceability </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In order to improve the traceability of biological medicinal products, the tradename and the batch </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">number of the administered product should be clearly recorded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Systemic injection reaction/ localised injection site reaction/ hypersensitivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab has been associated with systemic injection reactions, anaphylactic shock and delayed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypersensitivity reactions (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Acute reactions including anaphylactic reactions may develop during (within seconds) or within a few </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hours following administration of infliximab. If acute reactions occur, medical treatment should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sought immediately. For this reason, the initial intravenous administrations should take place where </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">emergency equipment, such as adrenaline, antihistamines, corticosteroids and an artificial airway is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immediately available. Patients may be pre-treated with e.g., an antihistamine, hydrocortisone and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">paracetamol to prevent mild and transient effects.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Localised injection site reactions predominantly of mild to moderate in nature included the following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions limited to injection site: erythema, pain, pruritus, swelling, induration, bruising, haematoma, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">oedema, coldness, paraesthesia, haemorrhage, irritation, rash, ulcer, urticaria, application site vesicles </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and scab were reported to be associated with infliximab subcutaneous treatment. Most of these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions may occur immediately or within 24 hours after subcutaneous injection. Most of these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions resolved spontaneously without any treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Antibodies to infliximab may develop and have been associated with an increased frequency of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion reactions when administered by intravenous infusion. A low proportion of the infusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions was serious allergic reactions. An association between development of antibodies to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab and reduced duration of response has also been observed with intravenously administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab. Concomitant administration of immunomodulators has been associated with lower </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">incidence of antibodies to infliximab and in the case of intravenously administered infliximab, a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduction in the frequency of infusion reactions. The effect of concomitant immunomodulator therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was more profound in episodically-treated patients than in patients given maintenance therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients who discontinue immunosuppressants prior to or during infliximab treatment are at greater </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">risk of developing these antibodies. Antibodies to infliximab cannot always be detected in serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">samples. If serious reactions occur, symptomatic treatment must be given and further infliximab must </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not be administered (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies, delayed hypersensitivity reactions have been reported. Available data suggest an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increased risk for delayed hypersensitivity with increasing infliximab free interval. Patients should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">advised to seek immediate medical advice if they experience any delayed adverse reaction (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.8). If patients are re-treated after a prolonged period, they must be closely monitored for signs and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">symptoms of delayed hypersensitivity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients must be monitored closely for infections including tuberculosis before, during and after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment with infliximab. Because the elimination of infliximab may take up to six months, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">monitoring should be continued throughout this period. Further treatment with infliximab must not be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">given if a patient develops a serious infection or sepsis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Caution should be exercised when considering the use of infliximab in patients with chronic infection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or a history of recurrent infections, including concomitant immunosuppressive therapy. Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be advised of and avoid exposure to potential risk factors for infection as appropriate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">45 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tumour necrosis factor alpha (T</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">NF&#x3b1;) mediates inflammation and modulates cellular immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">responses. Experimental data show that TNF&#x3b1; is essential for the clearing of intracellular infections. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical experience shows that host defence against infection is compromised in some patients treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It should be noted that suppression of TNF&#x3b1; may mask symptoms of infection such as fever. Early </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recognition of atypical clinical presentations of serious infections and of typical clinical presentation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of rare and unusual infections is critical in order to minimise delays in diagnosis and treatment.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients taking TNF-blockers are more susceptible to serious infections. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tuberculosis, bacterial infections, including sepsis and pneumonia, invasive fungal, viral, and other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">opportunistic infections have been observed in patients treated with infliximab. Some of these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infections have been fatal; the most frequently reported opportunistic infections with a mortality rate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of &gt;5% include pneumocystosis, candidiasis, listeriosis and aspergillosis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients who develop a new infection while undergoing treatment with infliximab, should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">monitored closely and undergo a complete diagnostic evaluation. Administration of infliximab should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or antifungal therapy should be initiated until the infection is controlled. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Tuberculosis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There have been reports of active tuberculosis in patients receiving infliximab. It should be noted that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the majority of these reports tuberculosis was extrapulmonary, presenting as either local or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disseminated disease.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Before starting treatment with infliximab, all patients must be evaluated for both active and inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2018;latent&#x2019;) tuberculosis. This evaluation should include a detailed medical history with personal history </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of tuberculosis or possible previous contact with tuberculosis and previous and/or current </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunosuppressive therapy. Appropriate screening tests, (e.g. tuberculin skin test, chest X-ray, and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Interferon Gamma Release Assay), should be performed in all patients (local recommendations may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">apply). It is recommended that the conduct of these tests should be recorded in the patient reminder </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">card. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients who are severely ill or immunocompromised. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If active tuberculosis is diagnosed, infliximab therapy must not be initiated (see section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">consulted. In all situations described below, the benefit/risk balance of infliximab therapy should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">very carefully considered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If inactive (&#x2018;latent&#x2019;) tuberculosis is diagnosed, treatment for latent tuberculosis must be started with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antituberculosis therapy before the initiation of infliximab, and in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommendations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients who have several or significant risk factors for tuberculosis and have a negative test for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">latent tuberculosis, antituberculosis therapy should be considered before the initiation of infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Use of antituberculosis therapy should also be considered before the initiation of infliximab in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">confirmed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Some cases of active tuberculosis have been reported in patients treated with infliximab during and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">after treatment for latent tuberculosis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">46 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(e.g. persistent cough, wasting/weight loss, low-grade fever) appear during or after infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Invasive fungal infections </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients treated with infliximab, an invasive fungal infection such as aspergillosis, candidiasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pneumocystosis, histoplasmosis, coccidioidomycosis or blastomycosis should be suspected if they </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">develop a serious systemic illness, and a physician with expertise in the diagnosis and treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">invasive fungal infections should be consulted at an early stage when investigating these patients.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Invasive fungal infections may present as disseminated rather than localised disease, and antigen and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antibody testing may be negative in some patients with active infection. Appropriate empiric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antifungal therapy should be considered while a diagnostic workup is being performed taking into </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">account both the risk for severe fungal infection and the risks of antifungal therapy.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For patients who have resided in or travelled to regions where invasive fungal infections such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">histoplasmosis, coccidioidomycosis, or blastomycosis are endemic, the benefits and risks of infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment should be carefully considered before initiation of infliximab therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fistulising Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with fistulising Crohn&#x2019;s disease with acute suppurative fistulas must not initiate infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapy until a source for possible infection, specifically abscess, has been excluded (see section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatitis B (HBV) reactivation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including infliximab, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">who are chronic carriers of this virus. Some cases have had fatal outcome. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients should be tested for HBV infection before initiating treatment with infliximab. For patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">who test positive for HBV infection, consultation with a physician with expertise in the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatitis B is recommended. Carriers of HBV who require treatment with infliximab should be closely </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">monitored for signs and symptoms of active HBV infection throughout therapy and for several months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">following termination of therapy. Adequate data of treating patients who are carriers of HBV with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antiviral therapy in conjunction with TNF-antagonist therapy to prevent HBV reactivation are not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available. In patients who develop HBV reactivation, infliximab should be stopped and effective </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antiviral therapy with appropriate supportive treatment should be initiated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatobiliary events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cases of jaundice and non-infectious hepatitis, some with features of autoimmune hepatitis, have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed in the post-marketing experience of infliximab. Isolated cases of liver failure resulting in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">liver transplantation or death have occurred. Patients with symptoms or signs of liver dysfunction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be evaluated for evidence of liver injury. If </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">jaundice and/or ALT elevations &#x2265;5 times the upper </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">limit of normal develop(s), infliximab should be discontinued, and a thorough investigation of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abnormality should be undertaken. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Concurrent administration of TNF-alpha inhibitor and anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Serious infections and neutropenia were seen in clinical studies with concurrent use of anakinra and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">another TNF&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-blocking agent, etanercept, with no added clinical benefit compared to etanercept alone. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Because of the nature of the adverse reactions seen with combination of etanercept and anakinra </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapy, similar toxicities may also result from the combination of anakinra and other TNF&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-blocking </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">agents. Therefore, the combination of infliximab and anakinra is not recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Concurrent administration of TNF-alpha inhibitor and abatacept </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">47 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies concurrent administration of TNF-antagonists and abatacept has been associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with an increased risk of infections including serious infections compared to TNF-antagonists alone, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">without increased clinical benefit. The combination of infliximab and abatacept is not recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Concurrent administration with other biological therapeutics </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is insufficient information regarding the concomitant use of infliximab with other biological </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapeutics used to treat the same conditions as infliximab. The concomitant use of infliximab with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">these biologics is not recommended because of the possibility of an increased risk of infection, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">other potential pharmacological interactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Switching between biological DMARDs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Care should be taken and patients should continue to be monitored when switching from one biologic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to another, since overlapping biological activity may further increase the risk for adverse reactions, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">including infection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vaccinations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is recommended that patients, if possible, be brought up to date with all vaccinations in agreement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with current vaccination guidelines prior to initiating Remsima therapy. Patients on infliximab may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receive concurrent vaccinations, except for live vaccines (see sections 4.5 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a subset of 90 adult patients with rheumatoid arthritis from the ASPIRE study a similar proportion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of patients in each treatment group (methotrexate plus: placebo [n = 17], 3 mg/kg [n = 27] or 6 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab [n = 46]) mounted an effective two-fold increase in titers to a polyvalent pneumococcal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vaccine, indicating that infliximab did not interfere with T-cell independent humoral immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">responses. However, studies from the published literature in various indications (e.g. rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthritis, psoriasis, Crohn&#x2019;s disease) suggest that non-live vaccinations received during treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anti-TNF therapies, including infliximab may elicit a lower immune response than in patients not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receiving anti-TNF therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Live vaccines/therapeutic infectious agents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients receiving anti-TNF therapy, limited data are available on the response to vaccination with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">live vaccines or on the secondary transmission of infection by live vaccines. Use of live vaccines can </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">result in clinical infections, including disseminated infections. The concurrent administration of live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vaccines with infliximab is not recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infant exposure</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In infants exposed </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> to infliximab, fatal outcome due to disseminated Bacillus Calmette-Gu&#xe9;rin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(BCG) infection has been reported following administration of BCG vaccine after birth. A twelve </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">month waiting period following birth is recommended before the administration of live vaccines to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infants exposed </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to infliximab. If infant infliximab serum levels are undetectable or infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration was limited to the first trimester of pregnancy, administration of a live vaccine might be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considered at an earlier timepoint if there is a clear clinical benefit for the individual infant (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infant exposure via breast milk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Administration of a live vaccine to a breastfed infant while the mother is receiving infliximab is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended unless infant infliximab serum levels are undetectable (see section 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Therapeutic infectious agents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Other uses of therapeutic infectious agents such as live attenuated bacteria (e.g., BCG bladder </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">instillation for the treatment of cancer) could result in clinical infections, including disseminated </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">48 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infections. It is recommended that therapeutic infectious agents not be given concurrently with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Autoimmune processes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The relative deficiency of TNF&#x3b1; caused by anti</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-TNF therapy may result in the initiation of an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">autoimmune process. If a patient develops symptoms suggestive of a lupus-like syndrome following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment with infliximab and is positive for antibodies against double-stranded DNA, further </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment with infliximab must not be given (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Neurological events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Use of TNF-blocking agents, including infliximab, has been associated with cases of new onset or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exacerbation of clinical symptoms and/or radiographic evidence of central nervous system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">demyelinating disorders, including multiple sclerosis, and peripheral demyelinating disorders, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">including Guillain-Barr&#xe9; syndrome. In patients with pre-existing or recent onset of demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disorders, the benefits and risks of anti-TNF treatment should be carefully considered before initiation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of infliximab therapy. Discontinuation of infliximab should be considered if these disorders develop.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the controlled portions of clinical studies of TNF-blocking agents, more cases of malignancies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">including lymphoma have been observed among patients receiving a TNF blocker compared with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">control patients. During clinical studies of infliximab across all approved indications the incidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lymphoma in infliximab-treated patients was higher than expected in the general population, but the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occurrence of lymphoma was rare. In the post-marketing setting, cases of leukaemia have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reported in patients treated with a TNF-antagonist. There is an increased background risk for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lymphoma and leukaemia in rheumatoid arthritis patients with long-standing, highly active, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inflammatory disease, which complicates risk estimation.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In an exploratory clinical study evaluating the use of infliximab in patients with moderate to severe </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chronic obstructive pulmonary disease (COPD), more malignancies were reported in infliximab-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treated patients compared with control patients. All patients had a history of heavy smoking. Caution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be exercised in considering treatment of patients with increased risk for malignancy due to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">heavy smoking. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">With the current knowledge, a risk for the development of lymphomas or other malignancies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients treated with a TNF-blocking agent cannot be excluded (see section 4.8). Caution should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exercised when considering TNF-blocking therapy for patients with a history of malignancy or when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considering continuing treatment in patients who develop a malignancy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Caution should also be exercised in patients with psoriasis and a medical history of extensive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunosuppressant therapy or prolonged PUVA treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Although subcutaneous administration is not indicated for children under age of 18 years, it should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">noted that malignancies, some fatal, have been reported among children, adolescents and young adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(up to 22 years of age) treated with TNF-</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blocking agents (initiation of therapy &#x2264;18 years of age), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">including infliximab in the post-marketing setting. Approximately half the cases were lymphomas. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The other cases represented a variety of different malignancies and included rare malignancies usually </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">associated with immunosuppression. A risk for the development of malignancies in patients treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with TNF-blockers cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treated with TNF-blocking agents including infliximab. This rare type of T-cell lymphoma has a very </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aggressive disease course and is usually fatal. Almost all patients had received treatment with AZA or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6-MP concomitantly with or immediately prior to a TNF-blocker. The vast majority of infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cases have occurred in patients with Crohn&#x2019;s disease or ulcerative colitis and most were reported in </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">49 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adolescent or young adult males. The potential risk with the combination of AZA or 6-MP and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab should be carefully considered. A risk for the development for hepatosplenic T-cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lymphoma in patients treated with infliximab cannot be excluded (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapy, including infliximab (see section 4.8). Periodic skin examination is recommended, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">particularly for patients with risk factors for skin cancer. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A population-based retrospective cohort study using data from Swedish national health registries </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">found an increased incidence of cervical cancer in women with rheumatoid arthritis treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab compared to biologics-na&#xef;ve patients or the general population, including those over 60 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">years of age. Periodic screening should continue in women treated with infliximab, including those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">over 60 years of age. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">before therapy and throughout their disease course. This evaluation should include colonoscopy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">biopsies per local recommendations. Current data do not indicate that infliximab treatment influences </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the risk for developing dysplasia or colon cancer. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Since the possibility of increased risk of cancer development in patients with newly diagnosed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dysplasia treated with infliximab is not established, the risk and benefits of continued therapy to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">individual patients should be carefully considered by the clinician. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Heart failure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab should be used with caution in patients with mild heart failure (NYHA class I/II). Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be closely monitored and infliximab must not be continued in patients who develop new or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">worsening symptoms of heart failure (see sections 4.3 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Haematologic reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There have been reports of pancytopenia, leukopenia, neutropenia, and thrombocytopenia in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receiving TNF-blockers, including infliximab. All patients should be advised to seek immediate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fever, bruising, bleeding, pallor). Discontinuation of infliximab therapy should be considered in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with confirmed significant haematologic abnormalities. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Others </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is limited safety experience of infliximab treatment in patients who have undergone surgical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">procedures, including arthroplasty. The long half-life of infliximab should be taken into consideration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">if a surgical procedure is planned. A patient who requires surgery while on infliximab should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">closely monitored for infections, and appropriate actions should be taken. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Failure to respond to treatment for Crohn&#x2019;s disease may indicate the presence of a fixed fibrotic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">stricture that may require surgical treatment. There is no evidence to suggest that infliximab worsens </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or causes fibrotic strictures. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Elderly </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The incidence of serious infections in infliximab-treated patients 65 years and older was greater than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in those under 65 years of age. Some of those had a fatal outcome. Particular attention regarding the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">risk for infection should be paid when treating the elderly (see section 4.8). </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sodium and sorbitol contents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially &#x2018;sodium-free&#x2019; and 45 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sorbitol per 1 mL (in each 120 mg dose).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No interaction studies have been performed.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In rheumatoid arthritis, psoriatic arthritis and Crohn&apos;s disease patients, there are indications that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant use of methotrexate and other immunomodulators reduces the formation of antibodies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">against infliximab and increases the plasma concentrations of infliximab. However, the results are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">uncertain due to limitations in the methods used for serum analyses of infliximab and antibodies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">against infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Corticosteroids do not appear to affect the pharmacokinetics of infliximab to a clinically relevant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">extent. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The combination of infliximab with other biological therapeutics used to treat the same conditions as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab, including anakinra and abatacept, is not recommended (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is recommended that live vaccines not be given concurrently with Remsima. It is also recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that live vaccines not be given to infants after </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> exposure to infliximab for 12 months following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">birth. If infant infliximab serum levels are undetectable or infliximab administration was limited to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">first trimester of pregnancy, administration of a live vaccine might be considered at an earlier </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">timepoint if there is a clear clinical benefit for the individual infant (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Administration of a live vaccine to a breastfed infant while the mother is receiving infliximab is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended unless infant infliximab serum levels are undetectable (see sections 4.4 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is recommended that therapeutic infectious agents not be given concurrently with infliximab (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fertility, pregnancy and lactation</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Women of childbearing potential </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Women of childbearing potential should consider the use of adequate contraception to prevent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy and continue its use for at least 6 months after the last infliximab treatment.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The moderate number of prospectively collected pregnancies exposed to infliximab resulting in live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">birth with known outcomes, including approximately 1,100 exposed during the first trimester, does not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">indicate an increase in the rate of malformation in the newborn.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on an observational study from Northern Europe, an increased risk (OR, 95% CI; p-value) for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C-section (1.50, 1.14-1.96; p = 0.0032), preterm birth (1.48, 1.05-2.09; p = 0.024), small for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">gestational age (2.79, 1.54-5.04; p = 0.0007), and low birth weight (2.03, 1.41-2.94; p = 0.0002) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed in women exposed during pregnancy to infliximab (with or without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunomodulators/corticosteroids, 270 pregnancies) as compared to women exposed to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunomodulators and/or corticosteroids only (6,460 pregnancies). The potential contribution of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exposure to infliximab and/or the severity of the underlying disease in these outcomes remains </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">unclear.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">51 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Due to its inhibition of TNF&#x3b1;, infliximab administered during pregnancy could affect normal immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">responses in the newborn. In a developmental toxicity study conducted in mice using an analogous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antibody that selectively inhibits the functional activity of mouse TNF&#x3b1;, there was no indication of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maternal toxicity, embryotoxicity or teratogenicity (see section 5.3).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The available clinical experience is limited. Infliximab should only be used during pregnancy if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clearly needed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab crosses the placenta and has been detected in the serum of infants up to 12 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">following birth. After </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> exposure to infliximab, infants may be at increased risk of infection, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">including serious disseminated infection that can become fatal. Administration of live vaccines (e.g., </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">BCG vaccine) to infants exposed to infliximab </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> is not recommended for 12 months after birth </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see sections 4.4 and 4.5). If infant infliximab serum levels are undetectable or infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration was limited to the first trimester of pregnancy, administration of a live vaccine might be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considered at an earlier timepoint if there is a clear clinical benefit for the individual infant. Cases of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">agranulocytosis have also been reported (see section 4.8).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Limited data from published literature indicate infliximab has been detected at low levels in human </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">milk at concentrations up to 5% of the maternal serum level. Infliximab has also been detected in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infant serum after exposure to infliximab via breast milk. While systemic exposure in a breastfed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infant is expected to be low because infliximab is largely degraded in the gastrointestinal tract, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration of live vaccines to a breastfed infant when the mother is receiving infliximab is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended unless infant infliximab serum levels are undetectable. Infliximab could be considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">for use during breast-feeding. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are insufficient preclinical data to draw conclusions on the effects of infliximab on fertility and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">general reproductive function (see section 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ability to drive and use machines</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima may have a minor influence on the ability to drive and use machines. Dizziness may occur </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">following administration of infliximab (see section 4.8).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Undesirable effects </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Summary of the safety profile  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Upper respiratory tract infection was the most common adverse drug reaction (ADR) reported in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical trials with infliximab, occurring in 25.3% of infliximab-treated patients compared with 16.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of control patients. The most serious ADRs associated with the use of TNF blockers that have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reported for infliximab include HBV reactivation, CHF (congestive heart failure), serious infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(including sepsis, opportunistic infections and TB), serum sickness (delayed hypersensitivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions), haematologic reactions, systemic lupus erythematosus/lupus-like syndrome, demyelinating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disorders, hepatobiliary events, lymphoma, HSTCL, leukaemia, Merkel cell carcinoma, melanoma, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sarcoidosis/sarcoid-like reaction, intestinal or perianal abscess (in Crohn&#x2019;s disease) and serious </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion reactions (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety profile of Remsima subcutaneous formulation from active rheumatoid arthritis (evaluated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in 168 and 175 patients for the subcutaneous infliximab group and the intravenous infliximab group, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">respectively), active Crohn&#x2019;s disease (evaluated in 59 and 38 patients for the subcutaneous infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group and the intravenous infliximab group, respectively) and active ulcerative colitis patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(evaluated in 38 and 40 patients for the subcutaneous infliximab group and the intravenous infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group, respectively) was overall similar to the safety profile of the intravenous formulation.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tabulated list of adverse reactions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Table 1 lists the ADRs based on experience from clinical studies as well as adverse reactions, some </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with fatal outcome, reported from post-marketing experience. Within the organ system classes, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions are listed under headings of frequency using the following categories: very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10); common (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/100 to &lt; </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10); uncommon (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/1,000 to &lt; </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/100); rare (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/10,000 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). Within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">each frequency grouping, undesirable effects are presented in order of decreasing seriousness. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:91pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adverse reactions in clinical studies and from post-marketing experience of intravenous </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:273pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">infliximab </span></b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Infections and infestations </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Viral infection (e.g. influenza, herpes virus infection). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bacterial infections (e.g. sepsis, cellulitis, abscess).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tuberculosis, fungal infections (e.g. candidiasis, onychomycosis). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Meningitis, opportunistic infections (such as invasive fungal infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[pneumocystosis, histoplasmosis, aspergillosis, coccidioidomycosis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cryptococcosis, blastomycosis], bacterial infections [atypical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mycobacterial, listeriosis, salmonellosis], and viral infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[cytomegalovirus]), parasitic infections, hepatitis B reactivation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vaccine breakthrough infection (after </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exposure to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab)*. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Neoplasms benign, malignant and unspecified (including cysts and polyps) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lymphoma, non-Hodgkin&#x2019;s lymphoma, Hodgkin&#x2019;s disease, leukaemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">melanoma, cervical cancer. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatosplenic T-cell lymphoma (primarily in adolescents and young </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adult males with Crohn&#x2019;s disease and ulcerative colitis), Merkel cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">carcinoma, Kaposi&#x2019;s sarcoma. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Blood and lymphatic system disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Neutropenia, leukopenia, anaemia, lymphadenopathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Thrombocytopenia, lymphopenia, lymphocytosis.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agranulocytosis (including infants exposed </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to infliximab), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">thrombotic thrombocytopenic purpura, pancytopenia, haemolytic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaemia, idiopathic thrombocytopenic purpura. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Immune system disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Allergic respiratory symptom. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Anaphylactic reaction, lupus-like syndrome, serum sickness or serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sickness-like reaction. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Anaphylactic shock, vasculitis, sarcoid-like reaction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Metabolism and nutrition disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dyslipidaemia. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Psychiatric disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Depression, insomnia. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Amnesia, agitation, confusion, somnolence, nervousness. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Apathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nervous system disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Headache. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vertigo, dizziness, hypoaesthesia, paraesthesia. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Seizure, neuropathy. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">53 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Transverse myelitis, central nervous system demyelinating disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(multiple sclerosis-like disease and optic neuritis), peripheral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">demyelinating disorders (such as Guillain-Barr&#xe9; syndrome, chronic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inflammatory demyelinating polyneuropathy and multifocal motor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">neuropathy). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cerebrovascular accidents in close temporal association with infusion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Eye disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Conjunctivitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Keratitis, periorbital oedema, hordeolum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:180pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:180pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Endophthalmitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Transient visual loss occurring during or within 2 hours of infusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Cardiac disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tachycardia, palpitation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cardiac failure (new onset or worsening), arrhythmia, syncope, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bradycardia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cyanosis, pericardial effusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Myocardial ischaemia/myocardial infarction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Vascular disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypotension, hypertension, ecchymosis, hot flush, flushing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Peripheral ischaemia, thrombophlebitis, haematoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Circulatory failure, petechia, vasospasm </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Respiratory, thoracic and mediastinal disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Upper respiratory tract infection, sinusitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lower respiratory tract infection (e.g. bronchitis, pneumonia), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dyspnoea, epistaxis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pulmonary oedema, bronchospasm, pleurisy, pleural effusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Interstitial lung disease (including rapidly progressive disease, lung </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fibrosis and pneumonitis) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Gastrointestinal disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Abdominal pain, nausea </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastrointestinal haemorrhage, diarrhoea, dyspepsia, gastroesophageal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reflux, constipation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Intestinal perforation, intestinal stenosis, diverticulitis, pancreatitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cheilitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatobiliary disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatic function abnormal, transaminases increased. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatitis, hepatocellular damage, cholecystitis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Autoimmune hepatitis, jaundice. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Liver failure. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Skin and subcutaneous tissue disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">New onset or worsening psoriasis including pustular psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(primarily palm &amp; soles), urticaria, rash, pruritus, hyperhidrosis, dry </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">skin, fungal dermatitis, eczema, alopecia. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bullous eruption, seborrhoea, rosacea, skin papilloma, hyperkeratosis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abnormal skin pigmentation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">multiforme, furunculosis, linear IgA bullous dermatosis (LABD), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:737pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">acute generalised exanthematous pustulosis (AGEP), lichenoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:762pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:762pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Worsening of symptoms of dermatomyositis. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">54 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Musculoskeletal and connective tissue disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:207pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Arthralgia, myalgia, back pain. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal and urinary disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Urinary tract infection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pyelonephritis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:142pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Reproductive system and breast disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:207pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vaginitis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">General disorders and administration site conditions </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infusion-related reaction, pain. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:205pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:205pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Chest pain, fatigue, fever, injection site reaction, chills, oedema. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Impaired healing. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Granulomatous lesion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:85pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Investigations </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Autoantibody positive. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:211pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Complement factor abnormal. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">* including bovine tuberculosis (disseminated BCG infection), see section 4.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Description of selected adverse drug reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Systemic injection reaction and localised injection site reaction in adult patients administered with </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Remsima subcutaneous formulation </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety profile of Remsima subcutaneous formulation in combination with methotrexate was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">evaluated in a Phase I/III parallel group study in patients with active rheumatoid arthritis. The safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">population consisted of 168 patients in the Remsima subcutaneous group and 175 patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima intravenous group. For study details, see Section 5.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The incidence rate of systemic injection reactions (e.g. rash, pruritus, flushing and oedema) was 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients per 100 patient-years in the Remsima subcutaneous group (from Week 6) and 2.1 patients per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 patient-years in the Remsima intravenous group who switched to Remsima subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration (from Week 30). All systemic injection reactions were mild to moderate.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The incidence rate of localised injection site reactions (e.g. injection site erythema, pain, pruritus and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">swelling) was 17.6 patients per 100 patient-years in the Remsima subcutaneous group (from Week 6) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 21.4 patients per 100 patient-years in those who switched to Remsima subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration (from Week 30). Most of these reactions were mild to moderate and resolved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">spontaneously without any treatment within a day. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a Phase I study conducted in patients with active Crohn&#x2019;s disease and active ulcerative colitis, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">safety population consisted of 97 patients in the Remsima subcutaneous group (59 patients with active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Crohn&#x2019;s disease and 38 patients with active ulcerative colitis) and 78 patients in the Remsima </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">intravenous group (38 patients with active Crohn&#x2019;s disease and 40 patients with active ulcerative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">colitis) from Part 1 and Part 2 of the study. For study details, see Section 5.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The incidence rate of systemic injection reactions (e.g. nausea and dizziness) was 2.3 patients per 100 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patient-years in the Remsima subcutaneous group (from Week 6) and there were no systemic injection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions reported in the Remsima intravenous group who switched to Remsima subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration (from Week 30). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The incidence rate of localised injection site reactions (e.g. injection site erythema, pain, pruritus, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bruising) was 23.3 patients per 100 patient-years in the Remsima subcutaneous group (from Week 6) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 7.5 patients per 100 patient-years in the Remsima intravenous group who switched to Remsima </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">55 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subcutaneous administration (from Week 30). All of these reactions were mild to moderate and mostly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">resolved spontaneously without any treatment within a few days. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In post-marketing experience, cases of anaphylactic-like reactions, including laryngeal/pharyngeal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">oedema and severe bronchospasm, and seizure have been associated with infliximab intravenous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration (see section 4.4). Cases of transient visual loss occurring during or within 2 hours of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab infusion have been reported. Events (some fatal) of myocardial ischaemia/infarction and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arrhythmia have been reported, some in close temporal association with infusion of infliximab; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cerebrovascular accidents have also been reported in close temporal association with infusion of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Delayed hypersensitivity </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies delayed hypersensitivity reactions have been uncommon and have occurred after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab-free intervals of less than 1 year. In the psoriasis studies with intravenous infliximab, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">delayed hypersensitivity reactions occurred early in the treatment course. Signs and symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">included myalgia and/or arthralgia with fever and/or rash, with some patients experiencing pruritus, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">facial, hand or lip oedema, dysphagia, urticaria, sore throat and headache. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are insufficient data on the incidence of delayed hypersensitivity reactions after infliximab-free </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">intervals of more than 1 year but limited data from clinical studies suggest an increased risk for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">delayed hypersensitivity with increasing infliximab-free interval (see section 4.4).</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a 1-year clinical study with repeated infusions of IV infliximab in patients with Crohn&apos;s disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(ACCENT I study), the incidence of serum sickness-like reactions was 2.4%. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Immunogenicity  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Intravenous formulation </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients who developed antibodies to infliximab were more likely (approximately 2-3 fold) to develop </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion-related reactions. Use of concomitant immunosuppressant agents appeared to reduce the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">frequency of infusion-related reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies using single and multiple infliximab doses ranging from 1 to 20 mg/kg, antibodies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to infliximab were detected in 14% of patients with any immunosuppressant therapy, and in 24% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients without immunosuppressant therapy. In rheumatoid arthritis patients who received the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended repeated treatment dose regimens with methotrexate, 8% of patients developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antibodies to infliximab. In psoriatic arthritis patients who received 5 mg/kg with and without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">methotrexate, antibodies occurred overall in 15% of patients (antibodies occurred in 4% of patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receiving methotrexate and in 26% of patients not receiving methotrexate at baseline). In Crohn&apos;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease patients who received maintenance treatment, antibodies to infliximab occurred overall in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.3% of patients receiving immunosuppressants and in 13.3% of patients not receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunosuppressants. The antibody incidence was 2-3 fold higher for patients treated episodically. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Due to methodological limitations, a negative assay did not exclude the presence of antibodies to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab. Some patients who developed high titres of antibodies to infliximab had evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduced efficacy. In psoriasis patients treated with infliximab as a maintenance regimen in the absence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of concomitant immunomodulators, approximately 28% developed antibodies to infliximab (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4: &quot;Systemic injection reaction/ localised injection site reaction/ hypersensitivity&quot;). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Because immunogenicity analyses are assay-specific, comparison of the incidence of antibodies to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab reported in this section with the incidence of antibodies in other studies may be misleading. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Subcutaneous formulation </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In rheumatoid arthritis patients on maintenance treatment, the incidence of anti-infliximab antibodies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">following the subcutaneous infliximab was demonstrated to be not higher than that of the intravenous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab and anti-infliximab antibodies had no significant impact on efficacy (determined by disease </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">56 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">activity score in 28 joints [DAS28] and American College of Rheumatology criteria 20 [ACR20]) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the safety profile.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In Crohn&apos;s disease and ulcerative colitis patients on maintenance treatment, the incidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anti-infliximab antibodies was not higher in patients who received subcutaneous infliximab in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">comparison to those who received intravenous infliximab and anti-infliximab antibodies had no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significant impact on efficacy (determined by clinical response and clinical remission according to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CDAI score for Crohn&apos;s disease patients or partial Mayo score for ulcerative colitis patients) and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">safety profile. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Infections </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tuberculosis, bacterial infections, including sepsis and pneumonia, invasive fungal, viral, and other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">opportunistic infections have been observed in patients receiving infliximab. Some of these infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have been fatal; the most frequently reported opportunistic infections with a mortality rate of &gt;5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">include pneumocystosis, candidiasis, listeriosis and aspergillosis (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies 36% of infliximab-treated patients were treated for infections compared with 25% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In rheumatoid arthritis clinical studies, the incidence of serious infections including pneumonia was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">higher in infliximab plus methotrexate-treated patients compared with methotrexate alone especially at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">doses of 6 mg/kg or greater (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In post-marketing spontaneous reporting, infections are the most common serious adverse reaction. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Some of the cases have resulted in a fatal outcome. Nearly 50% of reported deaths have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">associated with infection. Cases of tuberculosis, sometimes fatal, including miliary tuberculosis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tuberculosis with extra-pulmonary location have been reported (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies with infliximab in which 5,780 patients were treated, representing 5,494 patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">years, 5 cases of lymphomas and 26 non-lymphoma malignancies were detected as compared with no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lymphomas and 1 non-lymphoma malignancy in 1,600 placebo-treated patients representing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">941 patient years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In long-term safety follow-up of clinical studies with infliximab of up to 5 years, representing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6,234 patients-years (3,210 patients), 5 cases of lymphoma and 38 cases of non-lymphoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">malignancies were reported. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cases of malignancies, including lymphoma, have also been reported in the post-marketing setting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In an exploratory clinical study involving patients with moderate to severe COPD who were either </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">current smokers or ex-smokers, 157 adult patients were treated with infliximab at doses similar to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">those used in rheumatoid arthritis and Crohn&#x2019;s disease. Nine of these patients developed malignancies, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">including 1 lymphoma. The median duration of follow-up was 0.8 years (incidence 5.7% [95% CI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2.65%-10.6%]. There was one reported malignancy amongst 77 control patients (median duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">follow-up 0.8 years; incidence 1.3% [95% CI 0.03%-7.0%]). The majority of the malignancies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">developed in the lung or head and neck. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A population-based retrospective cohort study found an increased incidence of cervical cancer in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">women with rheumatoid arthritis treated with infliximab compared to biologics-na&#xef;ve patients or the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">general population, including those over 60 years of age (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">57 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In addition, post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treated with infliximab with the vast majority of cases occurring in Crohn&#x2019;s disease and ulcerative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">colitis, and most of whom were adolescent or young adult males (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Heart failure </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a Phase II study aimed at evaluating infliximab in CHF, higher incidence of mortality due to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">worsening of heart failure were seen in patients treated with infliximab, especially those treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the higher dose of 10 mg/kg (i.e. twice the maximum approved dose). In this study 150 patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">NYHA Class III-IV CHF (left ventricular ejection fraction </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">35%) were treated with 3 infusions of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab 5 mg/kg, 10 mg/kg, or placebo over 6 weeks. At 38 weeks, 9 of 101 patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab (2 at 5 mg/kg and 7 at 10 mg/kg) died compared to one death among the 49 patients on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There have been post-marketing reports of worsening heart failure, with and without identifiable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">precipitating factors, in patients taking infliximab. There have also been post-marketing reports of new </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">onset heart failure, including heart failure in patients without known pre-existing cardiovascular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease. Some of these patients have been under 50 years of age. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatobiliary events </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies, mild or moderate elevations of ALT and AST have been observed in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receiving infliximab without progression to severe hepatic injury. Elevations of ALT </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 x Upper </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Limit of Normal (ULN) have been observed (see Table 2). Elevations of aminotransferases were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed (ALT more common than AST) in a greater proportion of patients receiving infliximab than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in controls, both when infliximab was given as monotherapy and when it was used in combination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with other immunosuppressive agents. Most aminotransferase abnormalities were transient; however, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a small number of patients experienced more prolonged elevations. In general, patients who developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ALT and AST elevations were asymptomatic, and the abnormalities decreased or resolved with either </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">continuation or discontinuation of infliximab, or modification of concomitant therapy. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">post-marketing surveillance, cases of jaundice and hepatitis, some with features of autoimmune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatitis, have been reported in patients receiving infliximab (see section 4.4).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:93pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Proportion of patients with increased ALT activity in clinical studies using intravenous </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:273pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">infliximab</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Indication </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Number of patients</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:248pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Median follow-up </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:273pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(wks)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">4</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:366pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265; 3 x ULN</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:467pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265; 5 x ULN</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:141pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo infliximab placebo infliximab placebo infliximab placebo infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthritis</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:150pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">375 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:196pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1,087 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:250pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">58.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:301pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">58.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:350pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:401pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.8% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:502pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Crohn&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:150pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">324 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:196pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1,034 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:250pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">53.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:301pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">54.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:350pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2.2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:401pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:502pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ulcerative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">colitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:150pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">242 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:200pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">482 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:250pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">30.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:301pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">30.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:350pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:401pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:502pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.6% </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">58 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Indication </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:62pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Number of patients</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:248pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Median follow-up </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:273pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(wks)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">4</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:62pt;left:366pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265; 3 x ULN</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:62pt;left:467pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265; 5 x ULN</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:141pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo infliximab placebo infliximab placebo infliximab placebo infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ankylosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">spondylitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:152pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">76 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:200pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">275 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:250pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">24.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:298pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">101.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:350pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:401pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:502pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:152pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">98 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:200pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">191 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:250pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">18.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:301pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">39.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:350pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:401pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.8% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:502pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2.1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:152pt;left:150pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">281 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:152pt;left:196pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1,175 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:152pt;left:250pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">16.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:152pt;left:301pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:152pt;left:350pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:152pt;left:401pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7.7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:152pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:152pt;left:502pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 Placebo patients received methotrexate while infliximab patients received both infliximab and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">methotrexate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 Placebo patients in the 2 Phase III studies in Crohn&#x2019;s disease, ACCENT I and ACCENT II, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">received an initial dose of 5 mg/kg infliximab at study start and were on placebo in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintenance phase. Patients who were randomised to the placebo maintenance group and then later </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">crossed over to infliximab are included in the infliximab group in the ALT analysis. In the Phase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">IIIb trial in Crohn&#x2019;s disease, SONIC, placebo patients received AZA 2.5 mg/kg/day as active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">control in addition to placebo infliximab infusions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 Number of patients evaluated for ALT. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4 Median follow-up is based on patients treated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Antinuclear antibodies (ANA)/Anti-double-stranded DNA (dsDNA) antibodies </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Approximately half of infliximab-treated patients in clinical studies who were ANA negative at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline developed a positive ANA during the study compared with approximately one fifth of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo-treated patients. Anti-dsDNA antibodies were newly detected in approximately 17% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab-treated patients compared with 0% of placebo-treated patients. At the last evaluation, 57% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of infliximab-treated patients remained anti-dsDNA positive. Reports of lupus and lupus-like </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">syndromes, however, remain uncommon (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Other special populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Elderly </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In rheumatoid arthritis clinical studies, the incidence of serious infections was greater in infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">plus methotrexate-treated patients 65 years and older (11.3%) than in those under 65 years of age </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(4.6%). In patients treated with methotrexate alone, the incidence of serious infections was 5.2% in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients 65 years and older compared to 2.7% in patients under 65 (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting of suspected adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">listed in </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">Appendix V</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Overdose</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Single intravenous doses up to 20 mg/kg have been administered without toxic effects and repeated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">doses of Remsima subcutaneous formulation up to 240 mg have been administered without toxic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effects. There is no specific treatment for Remsima overdose. In the event of an overdose, the patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be treated symptomatically and supportive measures instituted as required.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacodynamic properties</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">59 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacotherapeutic group: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunosuppressants, tumour necrosis factor alpha (TNF&#x3b1;) inhibitors</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ATC code: L04AB02 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is a biosimilar medicinal product. Detailed information is available on the website of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">European Medicines Agency </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mechanism of action </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">soluble and transmembrane forms of TNF&#x3b1; but not to lymphotoxin &#x3b1; (TNF&#x3b2;).</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacodynamic effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab inhibits the functional activity of TNF&#x3b1; in a wide variety of </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bioassays. Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">prevented disease in transgenic mice that develop polyarthritis as a result of constitutive expression of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">human TNF&#x3b1; and when administered after disease onset, it allowed eroded joints to heal. </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab rapidly forms stable complexes with human </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">TNF&#x3b1;, a process that parallels the loss of TNF&#x3b1; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bioactivity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Elevated concentrations of TNF&#x3b1; have been found in the joints of rheumatoid arthritis patients and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">correlate with elevated disease activity. In rheumatoid arthritis, treatment with infliximab reduced </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infiltration of inflammatory cells into inflamed areas of the joint as well as expression of molecules </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mediating cellular adhesion, chemoattraction and tissue degradation. After infliximab treatment, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients exhibited decreased levels of serum interleukin 6 (IL-6) and C-reactive protein (CRP), and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increased haemoglobin levels in rheumatoid arthritis patients with reduced haemoglobin levels, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared with baseline. Peripheral blood lymphocytes further showed no significant decrease in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">number or in proliferative responses to </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mitogenic stimulation when compared with untreated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients&#x2019; cells. In psoriasis patients, treatment with infliximab resulted in decreases in epidermal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inflammation and normalisation of keratinocyte differentiation in psoriatic plaques. In psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthritis, short term treatment with infliximab reduced the number of T-cells and blood vessels in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">synovium and psoriatic skin. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Histological evaluation of colonic biopsies, obtained before and 4 weeks after administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab, revealed a substantial reduction in detectable TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. Infliximab treatment of Crohn&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease patients was also associated with a substantial reduction of the commonly elevated serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inflammatory marker, CRP. Total peripheral white blood cell counts were minimally affected in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab-treated patients, although changes in lymphocytes, monocytes and neutrophils reflected </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">shifts towards normal ranges. Peripheral blood mononuclear cells (PBMC) from infliximab-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients showed undiminished proliferative responsiveness to stimuli compared with untreated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients, and no substantial changes in cytokine production by stimulated PBMC were observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">following treatment with infliximab. Analysis of lamina propria mononuclear cells obtained by biopsy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of the intestinal mucosa showed that infliximab treatment caused a reduction in the number of cells </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">capable of expressing TNF</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x3b1;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and interferon </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x3b3;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. Additional histological studies provided evidence that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment with infliximab reduces the infiltration of inflammatory cells into affected areas of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">intestine and the presence of inflammation markers at these sites. Endoscopic studies of intestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mucosa have shown evidence of mucosal healing in infliximab-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical efficacy and safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adult rheumatoid arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Intravenous formulation </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of infliximab intravenous formulation was assessed in two multicentre, randomised, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">double-blind, pivotal clinical studies: ATTRACT and ASPIRE. In both studies concurrent use of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">stable doses of folic acid, oral corticosteroids (&#x2264;10</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> mg/day) and/or non-steroidal anti-inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">drugs (NSAIDs) was permitted. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">60 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The primary endpoints were the reduction of signs and symptoms as assessed by the ACR criteria </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(ACR20 for ATTRACT, landmark ACR-N for ASPIRE), the prevention of structural joint damage, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and the improvement in physical function. A reduction in signs and symptoms was defined to be at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">least a 20% improvement (ACR20) in both tender and swollen joint counts, and in 3 of the following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 criteria: (1) evaluator&#x2019;s global assessment, (2) patient&#x2019;s global assessment, (3) functional/disability </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">measure, (4) visual analogue pain scale and (5) erythrocyte sedimentation rate or C-reactive protein. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACR-N uses the same criteria as the ACR20, calculated by taking the lowest percent improvement in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">swollen joint count, tender joint count, and the median of the remaining 5 components of the ACR </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response. Structural joint damage (erosions and joint space narrowing) in both hands and feet was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">measured by the change from baseline in the total van der Heijde-modified Sharp score (0-440). The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Health Assessment Questionnaire (HAQ; scale 0-3) was used to measure patients&#x2019; average change </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">from baseline scores over time, in physical function. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The ATTRACT study evaluated responses at 30, 54 and 102 weeks in a placebo-controlled study of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">428 patients with active rheumatoid arthritis despite treatment with methotrexate. Approximately 50% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of patients were in functional Class III. Patients received placebo, 3 mg/kg or 10 mg/kg infliximab at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weeks 0, 2 and 6, and then every 4 or 8 weeks thereafter. All patients were on stable methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">doses (median 15 mg/wk) for 6 months prior to enrolment and were to remain on stable doses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">throughout the study. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Results from week 54 (ACR20, total van der Heijde-modified Sharp score and HAQ) are shown in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Table 3. Higher degrees of clinical response (ACR50 and ACR70) were observed in all infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">groups at 30 and 54 weeks compared with methotrexate alone. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A reduction in the rate of the progression of structural joint damage (erosions and joint space </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">narrowing) was observed in all infliximab groups at 54 weeks (Table 3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The effects observed at 54 weeks were maintained through 102 weeks. Due to a number of treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">withdrawals, the magnitude of the effect difference between infliximab and the methotrexate alone </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group cannot be defined. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ACR20, Structural Joint Damage and Physical Function at week 54, ATTRACT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:363pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Control</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q 8 wks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q 4 wks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q 8 wks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q 4 wks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">All </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with ACR20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response/Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">evaluated (%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">15/88 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(17%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">36/86 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(42%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">41/86 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(48%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">51/87 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(59%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">48/81 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(59%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">176/340 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(52%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Total score</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">d</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> (van der Heijde-modified Sharp score) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Change from baseline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Mean &#xb1; SD</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">c</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7.0 &#xb1; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:250pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.3 &#xb1; 6.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:304pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.6 &#xb1; 8.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:359pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.2 &#xb1; 3.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:416pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.7 &#xb1; 3.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:473pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.6 &#xb1; 5.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Interquartile range) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.5,9.7) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-1.5,3.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-2.5,3.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-1.5,2.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-3.0,1.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-1.8,2.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">deterioration/patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">evaluated (%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">c</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">13/64 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(20%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">34/71 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(48%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">35/71 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(49%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">37/77 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(48%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">44/66 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(67%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">150/285 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(53%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HAQ change from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline over time</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">e</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(patients evaluated) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">87 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">86 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">85 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">87 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">81 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">339 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mean &#xb1; SD</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">c</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.2 &#xb1; 0.3  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.4 &#xb1; 0.3  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.5 &#xb1; 0.4  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.5 &#xb1; 0.5  0.4 &#xb1; 0.4  0.4 &#xb1; 0.4  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">control = All patients had active RA despite treatment with stable methotrexate doses for 6 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">prior to enrolment and were to remain on stable doses throughout the study. Concurrent use of stable doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">oral corticosteroids (&#x2264;10</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> mg/day) and/or NSAIDs was permitted, and folate supplementation was given. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">b </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">all infliximab doses given in combination with methotrexate and folate with some on corticosteroids </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:761pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">and/or NSAIDs </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">61 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:363pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Control</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:257pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q 8 wks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:310pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q 4 wks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q 8 wks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:417pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">q 4 wks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">All </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">c </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">p &lt;0.001, for each infliximab treatment group vs. control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">d </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">greater values indicate more joint damage. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">e </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:116pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">HAQ = Health Assessment Questionnaire; greater values indicate less disability.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:129pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:141pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The ASPIRE study evaluated responses at 54 weeks in 1,004 methotrexate naive patients with early </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:154pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2264;3</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> years disease duration, median 0.6 years) active rheumatoid arthritis (median swollen and tender </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:167pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">joint count of 19 and 31, respectively). All patients received methotrexate (optimised to 20 mg/wk by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:179pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 8) and either placebo, 3 mg/kg or 6 mg/kg infliximab at weeks 0, 2, and 6 and every 8 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:192pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">thereafter. Results from week 54 are shown in Table 4. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:205pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After 54 weeks of treatment, both doses of infliximab + methotrexate resulted in statistically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:230pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significantly greater improvement in signs and symptoms compared to methotrexate alone as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">measured by the proportion of patients achieving ACR20, 50 and 70 responses. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In ASPIRE, more than 90% of patients had at least two evaluable X-rays. Reduction in the rate of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">progression of structural damage was observed at weeks 30 and 54 in the infliximab + methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">groups compared to methotrexate alone. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:319pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:94pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ACRn, Structural Joint Damage and Physical Function at week 54, ASPIRE </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:377pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab + MTX </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">+ MTX </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:321pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:391pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Combined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Subjects randomised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">282 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:321pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">359 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:391pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">363 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">722 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Percentage ACR improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mean &#xb1; SD</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">24.8 &#xb1; 59.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:321pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">37.3 &#xb1; 52.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:391pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">42.0 &#xb1; 47.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">39.6 &#xb1; 50.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Change from baseline in total van der Heijde-modified Sharp score</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mean &#xb1; SD</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.70 &#xb1; 9.61 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:321pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.42 &#xb1; 5.82 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:391pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.51 &#xb1; 5.55 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.46 &#xb1; 5.68 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.43 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:321pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.00 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:391pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.00 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.00 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Improvement from baseline in HAQ averaged over time from week 30 to week 54</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">c</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mean &#xb1; SD</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">d</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:252pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.68 &#xb1; 0.63 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:321pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.80 &#xb1; 0.65 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:391pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.88 &#xb1; 0.65 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.84 &#xb1; 0.65 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> p &lt;0.001, for each infliximab treatment group vs control. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">b </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">greater values indicate more joint damage. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">c </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">HAQ = Health Assessment Questionnaire; greater values indicate less disability. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">d </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">p = 0.030 and &lt;0.001 for the 3 mg/kg and 6 mg/kg treatment groups respectively vs. placebo + MTX.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Data to support dose titration in rheumatoid arthritis come from ATTRACT, ASPIRE and the START </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">study. START was a randomised, multicentre, double-blind, 3-arm, parallel-group safety study. In one </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of the study arms (group 2, n=329), patients with an inadequate response were allowed to dose titrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with 1.5 mg/kg increments from 3 up to 9 mg/kg. The majority (67%) of these patients did not require </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">any dose titration. Of the patients who required a dose titration, 80% achieved clinical response and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the majority (64%) of these required only one adjustment of 1.5 mg/kg. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Subcutaneous formulation </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of subcutaneous infliximab in rheumatoid arthritis patients was assessed in a randomised, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">parallel-group pivotal Phase I/III study consisting of two parts: Part 1 to determine the optimal dose of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subcutaneous infliximab and Part 2 to demonstrate non-inferiority in terms of efficacy of subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab compared to intravenous infliximab treatment in a double-blind setting.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In Part 2 of this study, among 357 patients who were enrolled to receive 2 doses of Remsima 3 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">intravenously at Weeks 0 and 2, 167 patients were randomised to receive Remsima 120 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subcutaneously at Week 6 and every 2 weeks up to Week 54, while 176 patients were randomised to </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">62 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receive Remsima 3 mg/kg intravenously at Weeks 6, 14 and 22 and then switched to Remsima 120 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subcutaneous at Week 30 once-every 2 weeks up to Week 54. Methotrexate was given concomitantly.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The primary endpoint of the study was the treatment difference of the change from baseline of DAS28 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(CRP) at Week 22. The estimate of treatment difference was 0.27 with corresponding lower limit of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the two-sided 95% confidence interval [CI] of 0.02 (95% CI: 0.02, 0.52), which was greater than the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pre-specified non-inferiority margin of -0.6 indicating non-inferiority of Remsima subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">formulation to Remsima intravenous formulation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The analysis of other efficacy endpoints showed that efficacy profile of Remsima subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">formulation compared to Remsima intravenous formulation in RA patients was generally comparable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in terms of disease activity measured by DAS28 (CRP and ESR) and ACR response up to Week 54. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The mean scores for DAS28 (CRP) and DAS28 (ESR) gradually decreased from baseline at each time </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">point until Week 54 in each treatment arm (see Table 5 and Table 6, respectively). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:175pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Mean (SD) Actual Values of DAS28 (CRP and ESR)</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:73pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Visit </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:234pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DAS28 (CRP) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:406pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DAS28 (ESR) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:195pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Remsima IV </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:204pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3 mg/kg</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.96pt">b</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:205pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(N=174) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:279pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Remsima SC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:292pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">120 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:290pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(N=165) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:366pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Remsima IV </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:375pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3 mg/kg</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.96pt">b</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:376pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(N=174) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:451pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Remsima SC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:464pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">120 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:462pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(N=165) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:73pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Baseline </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:206pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5.9 (0.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:291pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.0 (0.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:377pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.6 (0.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:463pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.7 (0.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:73pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:206pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.1 (1.2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:291pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.0 (1.2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:377pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.8 (1.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:463pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.6 (1.2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:73pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 22 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:204pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.5 (1.2)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:289pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.3 (1.1)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:377pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.1 (1.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:463pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.0 (1.1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:73pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 54 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:204pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2.9 (1.2)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:291pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2.8 (1.1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.4 (1.3)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:463pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.4 (1.2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Two-sided 95% CI for difference in the mean change from baseline for DAS28 (CRP) at Week 22 was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">well above the pre-defined non-inferiority margin of -0.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">b  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Remsima IV was switched to Remsima SC at Week 30</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:101pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Proportions of Patients Achieving Clinical Response According to the ACR Criteria </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:71pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:173pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">ACR20 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:315pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">ACR50 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:457pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">ACR70 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:73pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Visit </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:125pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Remsima IV </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:134pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3 mg/kg</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.96pt">a</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:136pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(N=174) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:196pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Remsima SC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:210pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">120 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:207pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(N=165) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:268pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Remsima IV </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:277pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3 mg/kg</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.96pt">a</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:278pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(N=174) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:338pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Remsima SC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:351pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">120 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:349pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(N=165) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:410pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Remsima IV </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:419pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3 mg/kg</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.96pt">a</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:420pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(N=174) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:480pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Remsima SC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:493pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">120 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:491pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(N=165) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:73pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:127pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">103 (59.2%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:199pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">107 (64.8%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:273pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">45 (25.9%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:343pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">47 (28.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:414pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">18 (10.3%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:485pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">19 (11.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:73pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 22 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:127pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">137 (78.7%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:199pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">139 (84.2%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:273pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">90 (51.7%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:343pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">85 (51.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:414pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">49 (28.2%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:485pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">46 (27.9%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:73pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 54 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:126pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">125 (71.8%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:199pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">132 (80.0%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">101 (58.0%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:341pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">108 (65.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:413pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">68 (39.1%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:485pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">77 (46.7%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Remsima IV was switched to Remsima SC at Week 30 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are no clinical trials with Remsima 120 mg given subcutaneously without intravenous loading </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">doses of infliximab in patients with rheumatoid arthritis. However, population pharmacokinetic and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacokinetic/pharmacodynamic modelling and simulation predicted comparable infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exposure (AUC over 8 weeks) and efficacy (DAS28 and ACR20 response) from Week 6 onward in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rheumatoid arthritis patients treated with Remsima 120 mg given without intravenous loading doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab when compared with Remsima 3 mg/kg given intravenously at Weeks 0, 2 and 6, and then </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">every 8 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">63 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adult Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Intravenous formulation </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Induction treatment in moderately to severely active Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of a single dose treatment with infliximab intravenous formulation was assessed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">108 patients with active Crohn&#x2019;s disease (CDAI </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">220 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">400) in a randomised, double-blinded, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo-controlled, dose-response study. Of these 108 patients, 27 were treated with the recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dosage of infliximab 5 mg/kg. All patients had experienced an inadequate response to prior </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">conventional therapies. Concurrent use of stable doses of conventional therapies was permitted, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">92% of patients continued to receive these therapies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The primary endpoint was the proportion of patients who experienced a clinical response, defined as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">decrease in CDAI by </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">70 points from baseline at the 4-week evaluation and without an increase in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">use of medicinal products or surgery for Crohn&#x2019;s disease. Patients who responded at week 4 were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">followed to week 12. Secondary endpoints included the proportion of patients in clinical remission at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 4 (CDAI &lt;150) and clinical response over time. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At week 4, following administration of a single dose, 22/27 (81%) of infliximab-treated patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receiving a 5 mg/kg dose achieved a clinical response vs. 4/25 (16%) of the placebo-treated patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p &lt;0.001). Also at week 4, 13/27 (48%) of infliximab-treated patients achieved a clinical remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(CDAI &lt;150) vs. 1/25 (4%) of placebo-treated patients. A response was observed within 2 weeks, with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a maximum response at 4 weeks. At the last observation at 12 weeks, 13/27 (48%) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab-treated patients were still responding. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Maintenance treatment in moderately to severely active Crohn&#x2019;s disease in adults </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of repeated infusions with intravenous infliximab was studied in a 1-year clinical study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(ACCENT I). A total of 573 patients with moderately to severely active Crohn&#x2019;s disease (CDAI </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">220 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">400) received a single infusion of 5 mg/kg at week 0. 178 of the 580 enrolled patients (30.7%) were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">defined as having severe disease (CDAI score &gt; 300 and concomitant corticosteroid and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunosuppressants) corresponding to the population defined in the indication (see section 4.1). At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 2, all patients were assessed for clinical response and randomised to one of 3 treatment groups; a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo maintenance group, 5 mg/kg maintenance group and 10 mg/kg maintenance group. All </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 groups received repeated infusions at week 2, 6 and every 8 weeks thereafter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Of the 573 patients randomised, 335 (58%) achieved clinical response by week 2. These patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">classified as week-2 responders and were included in the primary analysis (see Table 7). Among </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients classified as non-responders at week 2, 32% (26/81) in the placebo maintenance group and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">42% (68/163) in the infliximab group achieved clinical response by week 6. There was no difference </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">between groups in the number of late responders thereafter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The co-primary endpoints were the proportion of patients in clinical remission (CDAI &lt;150) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 30 and time to loss of response through week 54. Corticosteroid tapering was permitted after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 6. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">64 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:102pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on response and remission rate, data from ACCENT I (Week-2 responders) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:304pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACCENT I (Week-2 responders) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:347pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">% of Patients</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(n=110) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:335pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:330pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:341pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(n=113) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:439pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:446pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(n=112) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Median time to loss of response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">through week 54 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">19 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:338pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">38 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.002) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&gt;54 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 30 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:235pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:311pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:416pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical Response</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">27.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">51.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">59.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical Remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">20.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">38.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.003) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">45.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Steroid-Free Remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10.7 (6/56) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:331pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">31.0 (18/58) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.008) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:440pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">36.8 (21/57) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 54 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:235pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:358pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:467pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical Response</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">15.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">38.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">47.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical Remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">13.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">28.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.007) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">38.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sustained Steroid-Free </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remission</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5.7 (3/53) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:331pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">17.9 (10/56) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.075) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:440pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">28.6 (16/56) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.002) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a Reduction in CDAI </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;25% and &#x2265;70 points.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">b  CDAI &lt;150 at both Week 30 and 54 and not receiving corticosteroids in the 3 months prior to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 54 among patients who were receiving corticosteroids at baseline.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Beginning at week 14, patients who had responded to treatment, but subsequently lost their clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">benefit, were allowed to cross over to a dose of infliximab 5 mg/kg higher than the dose to which they </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were originally randomised. Eighty nine percent (50/56) of patients who lost clinical response on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab 5 mg/kg maintenance therapy after week 14 responded to treatment with infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 mg/kg. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Improvements in quality of life measures, a reduction in disease-related hospitalisations and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">corticosteroid use were seen in the infliximab maintenance groups compared with the placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintenance group at weeks 30 and 54. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab with or without AZA was assessed in a randomised, double-blind, active comparator study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(SONIC) of 508 adult patients with moderate to severe Crohn&#x2019;s disease (CDAI </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">220 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">450) who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">naive to biologics and immunosuppressants and had a median disease duration of 2.3 years. At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline 27.4% of patients were receiving systemic corticosteroids, 14.2% of patients were receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">budesonide, and 54.3% of patients were receiving 5-ASA compounds. Patients were randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receive AZA monotherapy, infliximab monotherapy, or infliximab plus AZA combination therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab was administered at a dose of 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks. AZA was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">given at a dose of 2.5 mg/kg daily. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The primary endpoint of the study was corticosteroid-free clinical remission at week 26, defined as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients in clinical remission (CDAI of &lt;150) who, for at least 3 weeks, had not taken oral systemic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">corticosteroids (prednisone or equivalent) or budesonide at a dose &gt;6 mg/day. For results see Table 8. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The proportions of patients with mucosal healing at week 26 were significantly greater in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab plus AZA combination (43.9%, p&lt;0.001) and infliximab monotherapy groups (30.1%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">p=0.023) compared to the AZA monotherapy group (16.5%). </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">65 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:74pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:86pt;left:95pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Percent of patients achieving corticosteroid-free clinical remission at Week 26, SONIC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:100pt;left:150pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:100pt;left:256pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">AZA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:238pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:100pt;left:335pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:329pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:100pt;left:427pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab + AZA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:421pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Combination therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 26 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:235pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:311pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:416pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">All randomised patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:253pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">30.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:249pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(51/170) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">44.4% (75/169) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:334pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p=0.006)* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:433pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">56.8% (96/169) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:443pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p&lt;0.001)* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">* p-values represent each infliximab treatment group vs. AZA monotherapy.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:178pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Similar trends in the achievement of corticosteroid-free clinical remission were observed at week 50. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Furthermore, improved quality of life as measured by IBDQ was observed with infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Induction treatment in fistulising active Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy was assessed in a randomised, double-blinded, placebo-controlled study in 94 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with fistulising Crohn&#x2019;s disease who had fistulae that were of at least 3 months&#x2019; duration. Thirty one of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">these patients were treated with infliximab intravenous formulation 5 mg/kg. Approximately 93% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the patients had previously received antibiotic or immunosuppressive therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Concurrent use of stable doses of conventional therapies was permitted, and 83% of patients continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to receive at least one of these therapies. Patients received three doses of either placebo or infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">at weeks 0, 2 and 6. Patients were followed up to 26 weeks. The primary endpoint was the proportion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of patients who experienced a clinical response, defined as </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50% reduction from baseline in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">number of fistulae draining upon gentle compression on at least two consecutive visits (4 weeks apart), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">without an increase in the use of medicinal products or surgery for Crohn&#x2019;s disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sixty eight percent (21/31) of infliximab-treated patients receiving a 5 mg/kg dose regimen achieved a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical response vs. 26% (8/31) placebo-treated patients (p=0.002). The median time to onset of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response in the infliximab-treated group was 2 weeks. The median duration of response was 12 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Additionally, closure of all fistulae was achieved in 55% of infliximab-treated patients compared with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">13% of placebo-treated patients (p=0.001). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Maintenance treatment in fistulising active Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of repeated infusions with infliximab in patients with fistulising Crohn&#x2019;s disease was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studied in a 1-year clinical study (ACCENT II). A total of 306 patients received 3 doses of intravenous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab 5 mg/kg at week 0, 2 and 6. At baseline, 87% of the patients had perianal fistulae, 14% had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abdominal fistulae, 9% had rectovaginal fistulae. The median CDAI score was 180. At week 14, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">282 patients were assessed for clinical response and randomised to receive either placebo or 5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab every 8 weeks through week 46. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week-14 responders (195/282) were analysed for the primary endpoint, which was time from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">randomisation to loss of response (see Table 9). Corticosteroid tapering was permitted after week 6. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:280pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:132pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on response rate, data from ACCENT II (Week-14 responders) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:153pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:302pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACCENT II (Week-14 responders) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:153pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:266pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:255pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(n=99) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:356pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:351pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:357pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(5 mg/kg) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(n=96) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:459pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">p-value </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Median time to loss of response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">through week 54 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:262pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">14 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:356pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&gt;40 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;0.001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 54 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:283pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:476pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fistula Response (%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:273pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">23.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:370pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">46.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:463pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Complete fistula response (%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:273pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">19.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:370pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">36.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:463pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.009 </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">66 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a A </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;50% reduction from baseline in the number of draining fistulas over a period of &#x2265;4 weeks.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">b Absence of any draining fistulas. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Beginning at week 22, patients who initially responded to treatment and subsequently lost their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response were eligible to cross over to active re-treatment every 8 weeks at a dose of infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg higher than the dose to which they were originally randomised. Among patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab 5 mg/kg group who crossed over because of loss of fistula response after week 22, 57% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(12/21) responded to re-treatment with infliximab 10 mg/kg every 8 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was no significant difference between placebo and infliximab for the proportion of patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sustained closure of all fistulas through week 54, for symptoms such as proctalgia, abscesses and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">urinary tract infection or for number of newly developed fistulas during treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance therapy with infliximab every 8 weeks significantly reduced disease-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hospitalisations and surgeries compared with placebo. Furthermore, a reduction in corticosteroid use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and improvements in quality of life were observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Subcutaneous formulation </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of subcutaneous infliximab in active Crohn&#x2019;s disease and active ulcerative colitis patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was assessed in an open-label, randomised, parallel-group, Phase I study consisting of two parts: Part </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 to determine the optimal dose of subcutaneous infliximab and Part 2 to demonstrate non-inferiority </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in terms of PK of subcutaneous infliximab compared to intravenous infliximab treatment.</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In Part 1 of this study, 45 patients with active Crohn&#x2019;s disease were enrolled to receive 2 doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 5 mg/kg intravenously at Weeks 0 and 2 and subsequently 44 patients were randomised into </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">four cohorts to receive Remsima 5 mg/kg intravenously (n=13) at Week 6 and every 8 weeks up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 54, Remsima 120 mg subcutaneously (n=11), Remsima 180 mg subcutaneously (n=12) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 240 mg subcutaneously (n=8) at Week 6 and every 2 weeks up to Week 54.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In Part 2 of this study, among 136 patients (57 patients with active Crohn&#x2019;s disease and 79 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with active ulcerative colitis) who were enrolled to receive 2 doses of Remsima 5 mg/kg intravenously </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">at Weeks 0 and 2, 66 patients (28 patients with active Crohn&#x2019;s disease and 38 patients with active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ulcerative colitis) were randomised to receive Remsima 120/ 240 mg subcutaneously at Week 6 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">every 2 weeks up to Week 54, while 65 patients (25 patients with active Crohn&#x2019;s disease and 40 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with active ulcerative colitis) were randomised to receive Remsima 5 mg/kg intravenously at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 6, 14 and 22 and then switched to Remsima 120/ 240 mg subcutaneous formulation at Week 30 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">once-every 2 weeks up to Week 54. The dosage of Remsima 120/ 240 mg subcutaneous formulation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was determined based on the patient&#x2019;s body weight at Week 6 for those who received Remsima </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subcutaneously and at Week 30 for those who switched to Remsima subcutaneous formulation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Remsima subcutaneous </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">120 mg for patients &lt;80 kg; 240 mg for patients &#x2265;80 kg).</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In active Crohn&#x2019;s disease patients, the descriptive efficacy results following Remsima 120 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subcutaneous formulation were generally comparable to Remsima 5 mg/kg intravenous formulation in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">terms of clinical response (CDAI-70 response </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">defined as a decrease in CDAI by &#x2265;70 points and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CDAI-100 response defined as </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;100 points from baseline), clinical remission (defined as an abso</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lute </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CDAI score of &lt;150 points) and endoscopy assessments (endoscopic response defined as a decrease in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50% of overall Simplified Endoscopic Activity Score for Crohn&#x2019;s Disease (SES-CD) score from the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline value and endoscopic remission defined as an absolute SES-CD score of </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 points). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adult ulcerative colitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Intravenous formulation </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of intravenous infliximab were assessed in two (ACT 1 and ACT 2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">randomised, double-blind, placebo-controlled clinical studies in adult patients with moderately to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">severely active ulcerative colitis (Mayo score 6 to 12; Endoscopy subscore </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 2) with an inadequate </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">67 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response to conventional therapies [oral corticosteroids, aminosalicylates and/or immunomodulators </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(6-MP, AZA)]. Concomitant stable doses of oral aminosalicylates, corticosteroids, and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunomodulatory agents were permitted. In both studies, patients were randomised to receive either </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo, 5 mg/kg infliximab, or 10 mg/kg infliximab at weeks 0, 2, 6, 14 and 22, and in ACT 1 at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weeks 30, 38 and 46. Corticosteroid taper was permitted after week 8. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:277pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 10 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:95pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on clinical response, clinical remission and mucosal healing at Weeks 8 and 30. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:221pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Combined data from ACT 1 &amp; 2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:250pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:320pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:389pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:463pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Combined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Subjects randomised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:260pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">244 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:330pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">242 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">242 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:477pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">484 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Percentage of subjects in clinical response and in sustained clinical response</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical response at Week 8</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:254pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">33.2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">66.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">65.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">66.1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical response at Week 30</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:254pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">27.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">49.6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">55.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">52.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sustained response (clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response at both Week 8 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 30)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:254pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">19.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">45.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:410pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">49.6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:486pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">47.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Percentage of subjects in clinical remission and sustained remission</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical remission at Week 8</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:254pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10.2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">36.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">29.8% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">33.1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical remission at Week 30</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:254pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">13.1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">29.8% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">36.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">33.1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sustained remission(in remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">at both Week 8 and Week 30)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:268pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:256pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">19.0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:410pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">24.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:486pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">21.7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Percentage of subjects with mucosal healing</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mucosal healing at Week 8</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:254pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">32.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">61.2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">60.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">60.7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mucosal healing at Week 30</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:254pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">27.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">48.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">52.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50.6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a p &lt;0.001, for each infliximab treatment group vs. placebo.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of infliximab through week 54 was assessed in the ACT 1 study. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At 54 weeks, 44.9% of patients in the combined infliximab treatment group were in clinical response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to 19.8% in the placebo treatment group (p&lt;0.001). Clinical remission and mucosal healing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occurred in a greater proportion of patients in the combined infliximab treatment group compared to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the placebo treatment group at week 54 (34.6% vs. 16.5%, p&lt;0.001 and 46.1% vs. 18.2%, p&lt;0.001, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">respectively). The proportions of patients in sustained response and sustained remission at week 54 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were greater in the combined infliximab treatment group than in the placebo treatment group (37.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vs. 14.0%, p&lt;0.001; and 20.2% vs. 6.6%, p&lt;0.001, respectively). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A greater proportion of patients in the combined infliximab treatment group were able to discontinue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">corticosteroids while remaining in clinical remission compared to the placebo treatment group at both </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 30 (22.3% vs. 7.2%, p &lt;0.001, pooled ACT 1 &amp; ACT 2 data) and week 54 (21.0% vs. 8.9%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">p=0.022, ACT 1 data). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The pooled data analysis from the ACT 1 and ACT 2 studies and their extensions, analysed from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline through 54 weeks, demonstrated a reduction of ulcerative colitis-related hospitalisations and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">surgical procedures with infliximab treatment. The number of ulcerative colitis-related hospitalisations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was significantly lower in the 5 and 10 mg/kg infliximab treatment groups than in the placebo group </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(mean number of hospitalisations per 100 subject-years: 21 and 19 vs. 40 in the placebo group; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">p=0.019 and p=0.007, respectively). The number of ulcerative colitis-related surgical procedures was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">also lower in the 5 and 10 mg/kg infliximab treatment groups than in the placebo group (mean number </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of surgical procedures per 100 subject-years: 22 and 19 vs. 34</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">; </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">p=0.145 and p=0.022, respectively). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The proportion of subjects who underwent colectomy at any time within 54 weeks following the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infusion of study agent were collected and pooled from the ACT 1 and ACT 2 studies and their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">extensions. Fewer subjects underwent colectomy in the 5 mg/kg infliximab group (28/242 or 11.6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[N.S.]) and the 10 mg/kg infliximab group (18/242 or 7.4% [p=0.011]) than in the placebo group </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(36/244; 14.8%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">68 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The reduction in incidence of colectomy was also examined in another randomised, double-blind study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(C0168Y06) in hospitalised patients (n=45) with moderately to severely active ulcerative colitis who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">failed to respond to intravenous corticosteroids and who were therefore at higher risk for colectomy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Significantly fewer colectomies occurred within 3 months of study infusion in patients who received a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">single dose of 5 mg/kg infliximab compared to patients who received placebo (29.2% vs. 66.7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">respectively, p=0.017). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In ACT 1 and ACT 2, infliximab improved quality of life, confirmed by statistically significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">improvement in both a disease specific measure, IBDQ, and by improvement in the generic 36-item </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">short form survey SF-36. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Subcutaneous formulation </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of subcutaneous infliximab in active ulcerative colitis patients was assessed in Part 2 of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">an open-label, randomised, parallel-group, Phase I study. For study details, see Section 5.1 on Crohn&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease, subcutaneous formulation.</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In active ulcerative colitis patients, the descriptive efficacy results following Remsima 120 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subcutaneous formulation were generally comparable to Remsima 5 mg/kg intravenous formulation in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">terms of clinical response (defined as a decrease from baseline in total Mayo score of at least 3 points </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and at least 30% or a decrease from baseline in partial Mayo score at least 2 points, with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">accompanying decrease from baseline in the subscore for rectal bleeding of at least 1 point, or an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">absolute subscore for rectal bleeding of 0 or 1), clinical remission (defined as a total Mayo score of </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">points with no individual subscore exceeding 1 point, or partial Mayo score of </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 point) and mucosal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">healing (defined as absolute endoscopic subscore of 0 or 1 from Mayo Scoring System). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adult ankylosing spondylitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Intravenous formulation </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Efficacy and safety of infliximab intravenous formulation were assessed in two multicentre, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">double-blind, placebo-controlled studies in patients with active ankylosing spondylitis (Bath </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ankylosing Spondylitis Disease Activity Index [BASDAI] score &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4 and spinal pain &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 4 on a scale of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1-10). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the first study (P01522), which had a 3-month double-blind phase, 70 patients received either </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg infliximab or placebo at weeks 0, 2, 6 (35 patients in each group). At week 12, placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients were switched to infliximab 5 mg/kg every 6 weeks up to week 54. After the first year of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">study, 53 patients continued into an open-label extension to week 102. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the second clinical study (ASSERT), 279 patients were randomised to receive either placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Group 1, n=78) or 5 mg/kg infliximab (Group 2, n=201) at 0, 2 and 6 weeks and every 6 weeks to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 24. Thereafter, all subjects continued on infliximab every 6 weeks to week 96. Group 1 received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg infliximab. In Group 2, starting with the week </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">36 infusion, patients who had a BASDAI &#x2265;3 at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 consecutive visits, received 7.5 mg/kg infliximab every 6 weeks thereafter through week 96. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In ASSERT, improvement in signs and symptoms was observed as early as week 2. At week 24, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">number of ASAS 20 responders was 15/78 (19%) in the placebo group, and 123/201 (61%) in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg infliximab group (p&lt;0.001). There were 95 subjects from group 2 who continued on 5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">every 6 weeks. At 102 weeks there were 80 subjects still on infliximab treatment and among those, 71 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(89%) were ASAS 20 responders. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In P01522, improvement in signs and symptoms was also observed as early as week 2. At week 12, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the number of BASDAI 50 responders were 3/35 (9%) in the placebo group, and 20/35 (57%) in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg group (p&lt;0.01). There were 53 subjects who continued on 5 mg/kg every 6 weeks. At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">102 weeks there were 49 subjects still on infliximab treatment and among those, 30 (61%) were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">BASDAI 50 responders. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">69 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In both studies, physical function and quality of life as measured by the BASFI and the physical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">component score of the SF-36 were also improved significantly. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adult psoriatic arthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Intravenous formulation </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Efficacy and safety of infliximab intravenous formulation were assessed in two multicentre, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">double-blind, placebo-controlled studies in patients with active psoriatic arthritis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the first clinical study (IMPACT), efficacy and safety of infliximab were studied in 104 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with active polyarticular psoriatic arthritis. During the 16-week double-blind phase, patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">either 5 mg/kg infliximab or placebo at weeks 0, 2, 6, and 14 (52 patients in each group). Starting at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 16, placebo patients were switched to infliximab and all patients subsequently received 5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab every 8 weeks up to week 46. After the first year of the study, 78 patients continued into an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">open-label extension to week 98. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the second clinical study (IMPACT 2), efficacy and safety of infliximab were studied in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">200 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with active psoriatic arthritis (&#x2265;5 swollen joints and &#x2265;5 tender joints). Forty</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> six percent of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients continued on stable doses of methotrexate (&#x2264;25</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> mg/week). During the 24-week double-blind </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">phase, patients received either 5 mg/kg infliximab or placebo at weeks 0, 2, 6, 14, and 22 (100 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in each group). At week 16, 47 placebo patients with &lt;10% improvement from baseline in both </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">swollen and tender joint counts were switched to infliximab induction (early escape). At week 24, all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo-treated patients crossed over to infliximab induction. Dosing continued for all patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">through week 46. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Key efficacy results for IMPACT and IMPACT 2 are shown in Table 11 below: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:277pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 11 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:169pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ACR and PASI in IMPACT and IMPACT 2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:219pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">IMPACT </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:401pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">IMPACT 2* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:152pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:152pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Week 16) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:213pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:213pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Week 16) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:277pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:277pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Week 98) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Week 24) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Week 24) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:466pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:466pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Week 54) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">randomised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:172pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:234pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N/A</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:358pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:420pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:484pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACR response  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:177pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:177pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:172pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:240pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:240pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:234pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:303pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:303pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:298pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">78 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:366pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:366pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:358pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:429pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:429pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:420pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:492pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:492pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:484pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACR 20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:159pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 (10%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:219pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">34 (65%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:283pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">48 (62%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:345pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">16 (16%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:408pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">54 (54%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">53 (53%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACR 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:162pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0 (0%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:219pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">24 (46%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:283pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">35 (45%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:351pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4 (4%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:408pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">41 (41%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">33 (33%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACR 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:162pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0 (0%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:219pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">15 (29%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:283pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">27 (35%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:351pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 (2%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:408pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">27 (27%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">20 (20%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PASI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:177pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:240pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:303pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:366pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:366pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:360pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">87 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:429pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:429pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:423pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">83 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:492pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:492pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:487pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">82 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:104pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PASI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">75 response** </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:177pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:240pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:303pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:351pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 (1%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:408pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50 (60%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:467pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">40 (48.8%) </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">* ITT-analysis where subjects with missing data were included as non-responders. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a Week 98 data for IMPACT includes combined placebo crossover and infliximab patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">entered the open-label extension. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">b Based on patients with PASI &gt;2.5 at baseline for IMPACT, and patients with &gt;3% BSA psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">skin involvement at baseline in IMPACT 2. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">** PASI 75 response for IMPACT not included due to low N; p&lt;0.001 for infliximab vs. placebo at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 24 for IMPACT 2. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In IMPACT and IMPACT 2, clinical responses were observed as early as week 2 and were maintained </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">through week 98 and week 54, respectively. Efficacy has been demonstrated with or without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant use of methotrexate. Decreases in parameters of peripheral activity characteristic of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">psoriatic arthritis (such as number of swollen joints, number of painful/tender joints, dactylitis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">presence of enthesopathy) were seen in the infliximab-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Radiographic changes were assessed in IMPACT 2. Radiographs of hands and feet were collected at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline, weeks 24 and 54. Infliximab treatment reduced the rate of progression of peripheral joint </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">damage compared with placebo treatment at the week 24 primary endpoint as measured by change </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">from baseline in total modified vdH-S score (mean &#xb1; SD score was 0.82 &#xb1; 2.62 in the placebo group </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared with -0.70 &#xb1; 2.53 in the infliximab group; p&lt;0.001). In the infliximab group, the mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">change in total modified vdH-S score remained below 0 at the week 54 timepoint. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab-treated patients demonstrated significant improvement in physical function as assessed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HAQ. Significant improvements in health-related quality of life were also demonstrated as measured </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">by the physical and mental component summary scores of the SF-36 in IMPACT 2. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adult psoriasis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Intravenous formulation </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of infliximab intravenous formulation was assessed in two multicentre, randomised, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">double-blind studies: SPIRIT and EXPRESS. Patients in both studies had plaque psoriasis (Body </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Surface Area [BSA] &#x2265;10% and Psoriasis Area and Severity Index [PASI] score &#x2265;12). The primary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">endpoint in both studies was the </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">percent of patients who achieved &#x2265;75% improvement in PASI from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline at week 10. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">SPIRIT evaluated the efficacy of infliximab induction therapy in 249 patients with plaque psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that had previously received PUVA or systemic therapy. Patients received either 3 or 5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab or placebo infusions at weeks 0, 2 and 6. Patients with a PGA score &#x2265;3 were eligible to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receive an additional infusion of the same treatment at week 26. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In SPIRIT, the proportion of patients achieving PASI 75 at week 10 was 71.7% in the 3 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab group, 87.9% in the 5 mg/kg infliximab group, and 5.9% in the placebo group (p&lt;0.001). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">By week 26, twenty weeks after the last induction dose, 30% of patients in the 5 mg/kg group and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">13.8% of patients in the 3 mg/kg group were PASI 75 responders. Between weeks 6 and 26, symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of psoriasis gradually returned with a median time to disease relapse of &gt;20 weeks. No rebound was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EXPRESS evaluated the efficacy of infliximab induction and maintenance therapy in 378 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with plaque psoriasis. Patients received 5 mg/kg infliximab- or placebo-infusions at weeks 0, 2 and 6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">followed by maintenance therapy every 8 weeks through week 22 in the placebo group and through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 46 in the infliximab group. At week 24, the placebo group crossed over to infliximab induction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapy (5 mg/kg) followed by infliximab maintenance therapy (5 mg/kg). Nail psoriasis was assessed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">using the Nail Psoriasis Severity Index (NAPSI). Prior therapy with PUVA, methotrexate, ciclosporin, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or acitretin had been received by 71.4% of patients, although they were not necessarily therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">resistant. Key results are presented in Table 12. In infliximab treated subjects, significant PASI 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">responses were apparent at the first visit (week 2) and PASI 75 responses by the second visit (week 6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Efficacy was similar in the subgroup of patients that were exposed to previous systemic therapies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to the overall study population. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">71 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:277pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 12 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:85pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Summary of PASI response, PGA response and percent of patients with all nails cleared at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:222pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Weeks 10, 24 and 50. EXPRESS</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:276pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Placebo &#x2192; Infliximab</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:306pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:297pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(at week 24) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:434pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:439pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 10 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:324pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:457pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:319pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">77 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">301 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;90% improvement</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 (1.3%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:428pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">172 (57.1%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;75% improvement </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 (2.6%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:428pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">242 (80.4%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;50% </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 (7.8%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">274 (91.0%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PGA of cleared (0) or minimal (1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 (3.9%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:426pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">242 (82.9%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> ab</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PGA of cleared (0), minimal (1), or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mild (2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">14 (18.2%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:426pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">275 (94.2%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> ab</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 24 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:324pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:457pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:319pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">77 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">276 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;90% improvement</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 (1.3%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:428pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">161 (58.3%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;75% improvement </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 (3.9%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:428pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">227 (82.2%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;50% improvement</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 (6.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">248 (89.9%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PGA of cleared (0) or minimal (1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 (2.6%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:428pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">203 (73.6%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PGA of cleared (0), minimal (1), or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mild (2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">15 (19.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:428pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">246 (89.1%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week 50 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:324pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:457pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">N </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:319pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">68 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">281 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;90% </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">34 (50.0%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">127 (45.2%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;75% improvement </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">52 (76.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">170 (60.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;50% improvement</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">61 (89.7%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">193 (68.7%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PGA of cleared (0) or minimal (1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">46 (67.6%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">149 (53.0%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PGA of cleared (0), minimal (1), or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mild (2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">59 (86.8%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">189 (67.3%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">All nails cleared</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.96pt">c</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:324pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:457pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 10 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/65(1.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:426pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">16/235 (6.8%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 24 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:298pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3/65 (4.6%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:420pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">58/223 (26.0%)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:293pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">27/64 (42.2%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:423pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">92/226 (40.7%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a p &lt;0.001, for each infliximab treatment group vs. control. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">b n = 292. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">c Analysis was based on subjects with nail psoriasis at baseline (81.8% of subjects). Mean baseline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">NAPSI scores were 4.6 and 4.3 in infliximab and placebo group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Significant improvements from baseline were demonstrated in DLQI (p&lt;0.001) and the physical and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mental component scores of the SF 36 (p&lt;0.001 for each component comparison). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The European Medicines Agency has waived the obligation to submit the results of studies with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reference medicinal product containing infliximab in all subsets of the paediatric population in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Crohn&#x2019;s disease (see section 4.2 for information on paediatric use). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacokinetic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Absorption and distribution  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Single subcutaneous injections of 120, 180 and 240 mg of infliximab yielded approximately dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">proportional increases in the maximum serum concentration (C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) and area under the concentration-</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">72 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">time curve (AUC). The apparent volume of distribution during the terminal phase (mean of 7.3 to 8.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">litres) was not dependent on the administered dose.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After single doses of 120, 180 and 240 mg of subcutaneous infliximab administered to healthy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subjects, the mean C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values were 10.0, 15.1 and 23.1 &#xb5;g/mL, respectively, and for all doses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infliximab could be detected in the serum for at least 12 weeks thereafter.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The bioavailability of subcutaneous infliximab, estimated in a population PK model, was 62% (95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CI: 60% - 64%).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After administration of infliximab 120 mg subcutaneously every 2 weeks (from Week 6 after 2 doses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of intravenous infliximab at Weeks 0 and 2) to patients with active rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitantly treated with MTX, the median (CV%) C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">trough</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> level at Week 22 (steady state) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">12.8 &#xb5;g/mL (80.1%).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After administration of infliximab 120 mg subcutaneously every 2 weeks (from Week 6 after 2 doses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of intravenous infliximab at Weeks 0 and 2) to patients with active Crohn&#x2019;s disease and active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ulcerative colitis, the median (CV%) C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">trough</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> level at Week 22 (steady state) was 20.1 &#xb5;g/mL (48.9%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on PK results from clinical studies in patients with active rheumatoid arthritis, active Crohn&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease and active ulcerative colitis and population PK modelling, C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">trough</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> levels at steady state would </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be higher after administration of infliximab 120 mg subcutaneous formulation given every 2 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared with infliximab 5 mg/kg intravenous formulation given every 8 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the dosing regimen with subcutaneous loading in patients with rheumatoid arthritis, the predicted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">median AUC value was 17,400 &#x3bc;g&#xb7;h/mL from Week 0 to 6 which was approximate</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ly 1.8 fold lower </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">than the predicted median AUC value for the dosing regimen with infliximab intravenous loading </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">doses (32,100 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x3bc;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">g&#xb7;h/mL). Whereas, the predicted median AUC values from Week 6 to 14 were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">comparable between the two dosing regimens with subcutaneous loading and intravenous loading </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(19,600 and 18,100 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x3bc;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">g&#xb7;h/mL, respectively).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Elimination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The elimination pathways for infliximab have not been characterised. Unchanged infliximab was not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">detected in urine. No major age- or weight-related differences in clearance or volume of distribution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were observed in rheumatoid arthritis patients.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In studies in healthy subjects, the mean (&#xb1; SD) apparent clearance of Remsima 120 mg administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subcutaneously was 19.3 &#xb1; 6.9 mL/hr.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the RA patients, the mean (&#xb1; SD) apparent clearance of Remsima 120 mg subcutaneous at steady </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">state was 18.8 &#xb1; 8.3 mL/hr. In the active Crohn&#x2019;s disease and active ulcerative colitis patients, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mean (&#xb1; SD) apparent clearance of Remsima 120 mg subcutaneous at steady state was 16.1 &#xb1; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.9 mL/hr. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The mean terminal half-life ranged from 11.3 days to 13.7 days for 120, 180 and 240 mg of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subcutaneous infliximab administered to healthy subjects.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Elderly </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The pharmacokinetics of infliximab injected via subcutaneous route in elderly patients has not been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studied.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">73 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Subcutaneous administration of Remsima is not recommended for paediatric use and no data are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available on the use of Remsima administered subcutaneously in the paediatric population. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatic and renal impairment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies with infliximab have not been performed in patients with liver or renal disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Preclinical safety data</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infliximab does not cross react with TNF&#x3b1; fro</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">m species other than human and chimpanzees. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Therefore, conventional preclinical safety data with infliximab are limited. In a developmental toxicity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">study conducted in mice using an analogous antibody that selectively inhibits the functional activity of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mo</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">use TNF&#x3b1;, there was no indication of maternal toxicity, embryotoxicity or teratogenicity. In a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fertility and general reproductive function study, the number of pregnant mice was reduced following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration of the same analogous antibody. It is not known whether this finding was due to effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">on the males and/or the females. In a 6-month repeated dose toxicity study in mice, using the same </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">analogous antibody against mouse TNF&#x3b1;, crystalline deposits were observed on the lens capsule of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">some of the treated male mice. No specific ophthalmologic examinations have been performed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients to investigate the relevance of this finding for humans. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Long-term studies have not been performed to evaluate the carcinogenic potential of infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies in mice </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">deficient in TNF&#x3b1; demonstrated no increase in tumours when challenged with known </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tumour initiators and/or promoters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The subcutaneous administration of Remsima to New Zealand White rabbits was well tolerated at the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">actual concentration to be used in humans. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">List of excipients</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Acetic acid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sodium acetate trihydrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sorbitol </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Polysorbate 80 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Water for injections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Incompatibilities</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shelf life</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">45 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Store in a refrigerator (2&#xb0;C - 8&#xb0;C).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Do not freeze. Keep the medicinal product in its outer carton in order to protect from light.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The medicinal product may be stored at temperatures up to a maximum of 25&#xb0;C for a period of up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">28 days. The medicinal product must be discarded if not used within the 28-day period.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nature and contents of container </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">74 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 120 mg solution for injection in pre-filled syringe </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 120 mg solution for injection in single-use pre-filled syringe (type I glass) with a plunger </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">stopper (flurotec-coated elastomer) and needle with a rigid needle shield. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Packs of: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:92pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 prefilled syringe (1 mL sterile solution) with 2 alcohol pads. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:92pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 prefilled syringes (1 mL sterile solution) with 2 alcohol pads. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:92pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4 prefilled syringes (1 mL sterile solution) with 4 alcohol pads. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:92pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 prefilled syringes (1 mL sterile solution) with 6 alcohol pads. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 120 mg solution for injection in pre-filled syringe with automatic needle guard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 120 mg solution for injection in single-use pre-filled syringe with automatic needle guard. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The syringe is made from type I glass with a plunger stopper (flurotec-coated elastomer) and needle </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with a rigid needle shield. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Packs of: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:92pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 prefilled syringe with automatic needle guard (1 mL sterile solution) with 2 alcohol pads. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:92pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 prefilled syringes with automatic needle guard (1 mL sterile solution) with 2 alcohol pads. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:92pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4 prefilled syringes with automatic needle guard (1 mL sterile solution) with 4 alcohol pads. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:92pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 prefilled syringes with automatic needle guard (1 mL sterile solution) with 6 alcohol pads. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 120 mg solution for injection in pre-filled pen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima 120 mg solution for injection in single-use pre-filled pen. The syringe inside the pen is made </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">from type 1 glass with a plunger stopper (flurotec-coated elastomer) and needle with a rigid needle </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">shield. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Packs of: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:92pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 prefilled pen (1 mL sterile solution) with 2 alcohol pads. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:92pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 prefilled pens (1 mL sterile solution) with 2 alcohol pads. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:92pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4 prefilled pens (1 mL sterile solution) with 4 alcohol pads.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:92pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 prefilled pens (1 mL sterile solution) with 6 alcohol pads.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not all pack sizes may be marketed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for disposal and other handling</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Remsima is a solution that is clear to opalescent, colourless to pale brown. Do not use if the solution is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cloudy, discoloured or contains visible particulate matter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After use, place the pre-filled syringe/ pre-filled syringe with automatic needle guard/ pre-filled pen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">into a puncture resistant container and discard as required by local regulations. Do not recycle the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">injecting device. Always keep the medicinal product out of the sight and reach of children. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">requirements. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Celltrion Healthcare Hungary Kft. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1062 Budapest </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">V&#xe1;ci &#xfa;t 1-3. WestEnd Office Building B torony </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:735pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hungary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:760pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">8. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBER(S)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/006 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/007 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/008 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/009 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/010 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/011 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/012 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/013 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/014 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/015 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/016 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/13/853/017 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">9. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of first authorisation: 22 November 2019</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:214pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>











































































</body>
</html> 

